AAD in D.C.: Networking Event Career Dermatology at its finest · 6 American Academy of Dermatology. Meeting. “

A Publication of the American Academy of Dermatology | Association

FRIDAY. MARCH 1, 2019

© Janssen Biotech, Inc. 2019 01/19 cp-74265v1

VISIT TREMFYA® ATBOOTH 3801

2019 AMERICAN ACADEMY OF DERMATOLOGYANNUAL MEETING

cp-74265v1_821516_v2.indd 1 1/31/19 2:13 PM

SEE MORE AAD ANNUAL MEETING NEWS! www.aadmeetingnews.org

I f you can, filter out the “noise” of politics for a moment. The truth is,

great work can happen in Washington, D.C., exemplified by the quality of education and events that make up this year’s AAD Annual Meeting. With a full schedule of education sessions, live demonstrations, and patient encounter workshops, learning and networking among dermatologists is at its finest.

The next five days offer “a whirlwind of educational offerings with updates on the latest advancements from across the specialty,” according to AAD Scientific Assembly Committee Chair Bob Brodell, MD.

“We live in a world where a significant percentage of medical students eschew the classroom

in favor of digital content. The 2019 AAD Annual Meeting is adjusting to these new realities,” Dr. Brodell said. “However, you will see more ‘hands-on’ coursework, self-assessment sessions, and presentations featuring creative topics and innovative techniques. Still, some things will not change! The Annual Meeting will always have a large number of people getting together under one roof to renew friendships, share knowledge, and learn.”

From panel discussions to a look at the latest products and services in the Exhibit Hall, myriad opportunities help dermatologists improve their practice, learn new techniques, hear the latest research, and expand their involvement in the Academy.

The AAD Annual Meeting features more than 350 educational sessions and hot topics, as well as opportunities to meet vendors, connect with the Academy, and network with colleagues.

The Exhibit Hall is open Friday, Saturday, and Sunday, with more than 350 exhibitors showcasing the latest products and services in dermatology.

The Connection, located in Hall D, offers lounges to meet colleagues, check email, charge your phone, vote in the AAD election, claim CME credits, and more.

Meet the candidates for president-elect and vice president-elect of the Academy during a live Town Hall on Friday, 12 to 1 p.m. in The Connection.

Meet and greet the AAD Board of Directors. Get to know your representatives, tell them what’s on your mind, and learn about current initiatives and programs. The event is Saturday, 12 to 1 p.m. in The Connection.

The AAD Resource Center serves as a central resource and features AAD services and new products. This includes CV/resume assistance and free professional headshots.

Connect with colleagues and employers at the Career Networking Event, 4:30-6:30 p.m. at the Marriott Marquis, Ballroom Salon 6.

“I’ve always seen the Annual Meeting as an opportunity — a chance to get out of my practice setting, learn the latest news and procedures, exchange ideas with fellow dermatologists, and work with my fellow members of the AAD to advance the specialty of dermatology,” said AAD President Suzanne Olbricht, MD. “I go home stimulated and ready to get back prepared to work to do the best job I can for my patients and my practice.”

INSIDE EMPOWERING PATIENTS 4 THE TRANSLATIONAL REVOLUTION 6 SHAPING AI FOR DERMATOLOGY 12 EXHIBIT HALL MAP 14 2018 MELANOMA GUIDELINES 20 SLIDING INTO DIGITAL 24

We live in a world where a significant percentage of medical students eschew the classroom in favor of digital content. The 2019 AAD Annual Meeting is adjusting to these new realities.

Bob Brodell, MDAAD Scientific Assembly

Committee Chair

The top concerns and interests of AAD members come to the forefront for the session “Hot Topics,” addressing those top-of-mind subjects established by registrant consensus.

The presentations and speakers are:

Acne: What’s New?Hilary Baldwin, MD

Biologics and Psoriasis: The Beat Goes OnMark Lebwohl, MD

Atopic Dermatitis: New DevelopmentsEmma Guttman, MD

Drug Eruptions: The Good, Bad, and UglyJ. Mark Jackson, MD

Melanoma Update 2018Darrell Rigel, MD

Hairy Matters: What’s New in Alopecia?Natasha Mesinkovska, MD

Cosmeceuticals: Naturally Absurd?Adam Friedman, MD

What’s New in Cosmetic Surgery?Anthony Benedetto, DO

WHAT’S HOT?

“Hot Topics” (S057)Monday, 1-4 p.mBallroom C

AAD in D.C.: Dermatology at its finest

JOB#: 1436851 CLIENT: Sandoz DESC: AAD Daily News Ad FILE NAME: SAN_AML_1436851_JA_D02.indd DATE: 1-28-2019 5:49 PM ROUND: 2PG: Ortiz-Krablin, Helena/Lake, Kathleen AD: Joe Mejia x3943 PM: Renee Roberts x4728 AE: Ron Kearns x5110 CW: Ryan Clark x4859 Last Saved: 1-28-2019 5:41 PMTRIM: 10.375” x 14” BLEED: 10.625” x 14.25” SAFETY: 9.375” x 13” PROD: Mike Haight x4245 INK Spec: 4 Color Process PRINT SCALE: NoneFONTS: Gotham Rounded (Bold, Medium, Light), Helvetica Neue LT Std (47 Light Condensed)

IMAGES: 436851_JA_fn.tif (CMYK; 300 ppi; 100%), 436851_JA_Products_fn.psd (CMYK; 300 ppi; 100%), Amlactin_4C.ai (76.1%), Amlactin_Icon_4C.ai (172%), Derm_Seal_2019_4C.ai (73.8%)INKS: Cyan, Magenta, Yellow, BlackDOC PATH: SAN_AML_1436851_JA_D02:Volumes...JA_D02:SAN_AML_1436851_JA_D02.inddNOTES: None

SAN_AML_1436851_JA_D02.indd Galley: 1

S&H PharmaGraphics

Disk

DATE

SIGNOFF

PG QC TC AD CD CW AE/AS ED PROD

THAN A MOISTURIZERAmLactin® gently exfoliatesplus deeply hydrates with beneficial levels of lactic acid

Experience the difference at booth #2925

SUNBURN ALERT: This product contains an alpha-hydroxy acid (AHA) that may increase your skin’s sensitivity to sunburn. Be sun smart: Use sunscreen, wear protective clothing, and limit sun exposure while using this product and for a week afterward.

© 2019 Sandoz Inc., 100 College Road West, Princeton, NJ 08540

S-ALH-1368903 01/2019

S:9.375”S:13”

T:10.375”T:14”

B:10.625”B:14.25”

DERMATOLOGY WORLD MEETING NEWS • FRIDAY • MARCH 1, 2019 3

JOB#: 1436851 CLIENT: Sandoz DESC: AAD Daily News Ad FILE NAME: SAN_AML_1436851_JA_D02.indd DATE: 1-28-2019 5:49 PM ROUND: 2PG: Ortiz-Krablin, Helena/Lake, Kathleen AD: Joe Mejia x3943 PM: Renee Roberts x4728 AE: Ron Kearns x5110 CW: Ryan Clark x4859 Last Saved: 1-28-2019 5:41 PMTRIM: 10.375” x 14” BLEED: 10.625” x 14.25” SAFETY: 9.375” x 13” PROD: Mike Haight x4245 INK Spec: 4 Color Process PRINT SCALE: NoneFONTS: Gotham Rounded (Bold, Medium, Light), Helvetica Neue LT Std (47 Light Condensed)

IMAGES: 436851_JA_fn.tif (CMYK; 300 ppi; 100%), 436851_JA_Products_fn.psd (CMYK; 300 ppi; 100%), Amlactin_4C.ai (76.1%), Amlactin_Icon_4C.ai (172%), Derm_Seal_2019_4C.ai (73.8%)INKS: Cyan, Magenta, Yellow, BlackDOC PATH: SAN_AML_1436851_JA_D02:Volumes...JA_D02:SAN_AML_1436851_JA_D02.inddNOTES: None

SAN_AML_1436851_JA_D02.indd Galley: 1

S&H PharmaGraphics

Disk

DATE

SIGNOFF

PG QC TC AD CD CW AE/AS ED PROD

THAN A MOISTURIZERAmLactin® gently exfoliatesplus deeply hydrates with beneficial levels of lactic acid

Experience the difference at booth #2925

SUNBURN ALERT: This product contains an alpha-hydroxy acid (AHA) that may increase your skin’s sensitivity to sunburn. Be sun smart: Use sunscreen, wear protective clothing, and limit sun exposure while using this product and for a week afterward.

© 2019 Sandoz Inc., 100 College Road West, Princeton, NJ 08540

S-ALH-1368903 01/2019

S:9.375”

S:13”

T:10.375”

T:14”

B:10.625”

B:14.25”

Vol. 30, No 1 March 1, 2019

PresidentSuzanne Olbricht, MD

Physician ReviewerMarta Van Beek, MD, MPH

Executive Director & CEOElaine Weiss, JD

Director, CommunicationsKatie Domanowski

Associate Director, PublishingRichard Nelson, MS

Managing Editor, Special Publications

Dean Monti, MFA

Creative ManagerNicole Torling

Senior Graphic DesignerTheresa Oloier

Printed in U.S.A. ©2019American Academy

of Dermatology Association9500 W. Bryn Mawr Ave, Ste 500

Rosemont, IL 60018-5216Phone (847) 330-0230;

Fax (847) 330-0050

Produced for the American Academy of Dermatology

By Ascend Integrated Media

A look at AAD’s Plenary sessionSunday’s speakers offer key insight

This year’s Plenary

speakers cover

a wide range of

topics. Learn more

about these seven

individuals and

what they plan

to share in their

presentations.

Paul Nghiem, MD, PhD“Less Toxic, More Effective: A Win-Win for Merkel Cell Carcinoma”

What does it mean to you to be selected for and speak at this year’s Plenary?Delivering the Van Scott/Frost lectureship is a career-highlight honor for me because I have always hoped my research would have impact in the care of patients. More importantly, I believe this event should help us come together to ensure Merkel cell carcinoma patients get the best possible multi-disciplinary care. Lives will literally be saved and unnecessary toxicities will be avoided due to the awareness that can come from this session.

Diane M. Thiboutot, MD“In Search of the Next Isotretinoin”

What is the key point you hope members will take away from your presentation?Acne remains an important disease that causes distress to millions of individuals and that analysis of large datasets in partnership with industry can accelerate drug discovery.

Robin Farmanfarmaian“Patient Empowerment in the Digital Age”

What does it mean to you to be selected for and speak at this year’s Plenary?I am incredibly honored to be selected for this year’s Plenary! As a chronic disease patient, as well as an entrepreneur working in health care, I have massive respect for physicians and other health care providers, and with good reason — they are the ones on the front lines working to save and improve other people’s lives. For decades, health care providers have helped me, and it is an honor to be able to give back to them in this small way.

Boris D. Lushniak, MD “I Acted and Behold, Service was Joy”

What is one insight you can share about the future of dermatology?

We, as dermatologists, need to be fully engaged in paving the pathway for the future of dermatology as a 21st century specialty. Embrace technology but don’t forget the art, the personal interactions, and the service mission of medicine.

George J. Hruza, MD, MBAPresident-Elect’s Address

How do you plan to address challenges to the profession in your role?Dermatology has the fastest rate of burnout increase in medicine. I will make sure that the Academy is there to support our members through a beefed-up Practice Management Center and reinvigorated advocacy at the federal and state level. A new quality improvement center will help our members improve the care they provide their patients. We will perform an in-depth review of all of our programs to enhance our effectiveness, transparency, and responsiveness to our members and the needs of dermatology.

Crystal L. Mackall, MD“Engineering T Cells for Cancer Therapy”

What is the key point you hope members will take away from your presentation? I am hopeful that I can educate the members regarding recent progress in using engineered T cells for cancer therapy and convey to the members the basis for optimism regarding the potential of this novel class of therapeutics.

Suzanne M. Olbricht, MDPresident’s Address

What has been one of the greatest challenges to the profession in the last year?The future of dermatology is strong. Dermatologists are energetic, passionate, and innovative. Innovating is critical because the practice of medicine will be vastly different in five years due to the digital revolution and advances in augmented intelligence. I encourage AAD members to embrace change and focus on our vision statement: Advancing excellence in dermatology.

Share your photos on Instagram to win big at the Annual Meeting!

The Instagram Challenge is back! Between Friday, Mar. 1, and Monday, Mar. 4, the @AADmember Instagram account will be hosting a photo challenge where attendees can submit pictures of themselves with their friends, colleagues, or mentors at the Annual Meeting. Participants must follow @AADmember and include the hashtag #AAD2019Challenge in the caption of their photo(s) to enter. A winner will be randomly chosen each day to win a $50 gift card, and a grand prize winner will be selected from the total submissions to win free registration to the 2020 Annual Meeting!

4 DERMATOLOGY WORLD MEETING NEWS • FRIDAY • MARCH 1, 2019

Several Th2 cytokines, including IL-13, are key drivers of atopic dermatitis.1

BECOME ANATOPIC DERMATITIS

DETECTIVE

Reference: 1. Gittler JK, Shemer A, Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2012;130(6):1344-1354.

LEO and the LEO Lion Design are registered trademarks of LEO Pharma A/S.©2019 LEO Pharma Inc. All rights reserved. MAT-22212 January 2019 Printed in USA.

FOR MORE INFORMATION CHECK OUT ADdetective.com

Review the case at

LEO Pharma Booth#3227

7 a.m.-5:30 p.m. AAD registration openLocation: Grand Lobby – Street Level The Connection Location: Hall D• View e-posters• Charge your phone in the

Networking Lounge• Utilize e-center to access

voting, claim CME, read emails, and check in for your flight home

8 a.m.-5 p.m.AAD Resource Center openLocation: Hall D

9 a.m.-5 p.m.Gross and Microscopic Symposium (S008) Location: Room 149AB

12-1 p.m.AAD Election 2019• Meet the Candidates • Live Town HallLocation: The Connection, Hall D Unopposed exhibit timeLocation: Exhibit Hall

1-3 p.m.Virtual Dermatopathology Self Assessment: Get Ready for Non-glass Slide Exams (F022) Location: Room 143C

3:30-5:30 p.m.Boards and Beyond (F034) Location: Room 203AB

4-5:30 p.m.Access to Care Learning CollaborativeLocation: Georgetown University Room, Marriott Marquis

4:30-6:30 p.m.AAD Career Networking Event Location: Marquis Ballroom Salon 6, Marriott Marquis, Washington DC

5:30-7 p.m.International Members ReceptionLocation: Marquis Ballroom Salon 5, Marriott Marquis, Washington DC

Early Career ReceptionLocation: Marquis Ballroom Salon 7-10, Marriott Marquis, Washington DC

7 p.m. (6:30 p.m. registration)Industry Non-CME Program: HANDS ON Psoriatic Disease: A Live & Augmented Reality Experience for Advancing Patient Care Despite Modern Time ConstraintsLocation: Renaissance Ballroom West A and B, Renaissance Washington, DC Downtown Hotel

From Novartis

Industry Non-CME Program: PD-1 Targeting Therapy in Advanced Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)Location: Liberty M-P, Marriott Marquis Washington, DC

From Sanofi Genzyme and Regeneron

Industry Non-CME Program: Understanding and Treating Psoriatic Disease in a New Generation of PatientsLocation: Renaissance Ballroom East, Renaissance Washington, DC Downtown Hotel

From UCB Inc.

TODAY’S HIGHLIGHTS

What is one insight you

will share about the future of dermatology?Farmanfarmaian: The use of AI will increase as more and more accurate data is aggregated for AI programs to learn. This is beneficial for the dermatology field, as one of the things AI is best at doing is pattern analysis. AI analysis programs serve as tools that can help physicians and patients catch some problems earlier, when they are easier to treat.

How is technology

impacting health care?Health care is shifting in two major ways. A combination of technology and costs is shifting the point of care to where the patient is located, versus the patient having to physically go to a brick and mortar clinic. Also, patients are becoming more empowered by these same forces — technology and costs — to be in control of their health care: When they want it, where they want it, and how they want it.

If virtual care is the wave of the

future, what are the cons of virtual care?While there are tons of benefits for using virtual care, like most things in life, there are also some cons. Physical human touch is important in the health care relationship, both on an emotional level for the patient and for assessment and diagnostics.

If the physician is relying on data collected by the patient, such as vital signs, there is a risk the equipment is not being used correctly without a physician present. In addition, when the physician is able to see a patient in person, they may notice or catch things that either the patient doesn’t think to mention, or the patient doesn’t know is a symptom or a data point for assessment. Lastly, communication with any subject is always more effective in person, and this can be especially important when dealing with the complexities of health care.

As a non-physician

looking in, what do you believe were the greatest challenges to physicians in the last year?As someone with a high-level viewpoint of health care and technology, not in dermatology specifically, I believe the challenges to the dermatology profession are likely the same as the challenges faced in all other specialties: the high costs of medications and treatments for their patients. No specialty is immune to these rapidly growing costs, combined with reimbursement becoming even more complicated and at times, reduced. This isn’t a dermatology-specific challenge. This is the biggest challenge in health care today.

Q A Empowering patients in the digital age

& :

“Patient Empowerment in the Digital Age.”Sunday, 8-11:30 a.m.Ballroom B

Q

Q

QQ

In her session, “Patient Empowerment in the Digital Age,” plenary guest speaker Robin Farmanfarmaian will address a host of current breakthroughs in medical technology that are fundamentally changing the way patients interact with their health care and providers. These include wearable sensors, improved point-of-care diagnostics, augmented intelligence (AI), and virtual care. Farmanfarmaian will discuss methods for integrating these new services and revenue streams into the dermatology practice.

Currently, Farmanfarmaian is working with a few early stage start-ups: as COO for Arc Fusion Programs; as co-founder and former executive director for the Organ Preservation Alliance; as vice president of Business Development for Invicta Medical; and as president of i4j ECO, a summit to disrupt unemployment through innovation to create jobs and meaningful work for everyone.

Learn more about Robin Farmanfarmaian at www.robinff.com.

Pick up your copy of the Onsite Meeting GuideThe 2019 Onsite Meeting Guide, Experience the AAD Annual Meeting, is available in racks throughout the Walter E. Washington Convention Center. It has all of the vital information you need about the meeting, such as:

• Key elements• Daily highlights• AAD honors and awards• Education information• Social media platforms

• Exhibit Hall floor plan and exhibitor lists

• Convention center maps

MEET THE AAD BOARD OF DIRECTORSSATURDAY, MARCH 2 • 12–1 p.m.

In The Connection, located in Hall D

The

THOUGHTLEADER

FORMULAStrategically Leverage

Your Expertise to Drive

Business & Career Goals

R O B I N F A R M A N F A R M A I A N

The ultimate form of career insurance is becoming known as

an expert...Robin’s book lays out a clear, effective strategy...”

— D O R I E C L A R K“

http://www.robinff.com

Several Th2 cytokines, including IL-13, are key drivers of atopic dermatitis.1

BECOME ANATOPIC DERMATITIS

DETECTIVE

Reference: 1. Gittler JK, Shemer A, Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2012;130(6):1344-1354.

LEO and the LEO Lion Design are registered trademarks of LEO Pharma A/S.©2019 LEO Pharma Inc. All rights reserved. MAT-22212 January 2019 Printed in USA.

FOR MORE INFORMATION CHECK OUT ADdetective.com

Review the case at

LEO Pharma Booth#3227

Empowering patients in the digital age


Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936-1080 © 2019 Novartis 1/19 T-COS-1362218

Discover theComplete

Cosentyx ApproachBooth #3021

These Industry Expert Sessions are promotional activities and are not approved for continuing education credit. The content of these sessions and opinions expressed by presenters are those of the Presenting Company or presenters and do not represent an endorsement by, nor imply that the products have been evaluated or approved by the

American Academy of Dermatology.

Novartis acts in accordance with the PhRMA Code on Interactions With Health Care Professionals. The PhRMA Code states that inclusion of a health care professional’s spouse or guest at an educational program is not appropriate. Your support of these ethical guidelines will help to ensure a high quality learning environment for all

participating health care professionals. Thank you.

Francisco A. Kerdel, MD, MBBS, BSc

Presented by:

Saturday, March 2, 201911:00 am – 11:45 am Program

Exhibit Hall AWalter E. Washington Convention Center

Washington, DCPlease arrive at 10:45 am to register

Meal will be provided.

Industry Expert Session 2

Ben Lockshin, MD, FAAD

Presented by:

Friday, March 1, 20192:45 pm – 3:30 pm Program


Washington, DCPlease arrive at 2:30 pm to register



Hear Expert Insights at Two Unique Educational Sessions

Join us for these exciting events at this year’s AAD Annual Meeting!

The first biologic treatment, dupilumab, is producing better or comparable clinical results to any of the pre-biologic era agents. The next step will be other biologics that can perhaps be administered every four to 12 weeks, followed by oral agents.

At least two different agents are in randomized clinical trials, with significant early results. More results may be presented at the AAD Annual Meeting.

Studies are emerging for topical and systemic treatments.

New biologics are emerging.

@AADmemberfacebook.com/AADmemberinstagram.com/aadmember

Get social with AADJoin the thousands of other dermatologists who are already following @aadmember, and be sure to use the official Annual Meeting hashtag #AAD19 in all your meeting-related posts and tweets.

The translational revolution in inflammatory skin diseasesT he scientific revolution

in the understanding of inflammatory skin

diseases as immune-mediated diseases that began in the late 1990s and early 2000s is evolving into a growing stream of new, revolutionary treatments. From initial breakthroughs in psoriasis to improved understanding of the pathogenesis of atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa, acne, and rosacea, the increased body of knowledge

is advancing treatment results that patients and their physicians could only dream about a decade ago.

These advances in the mechanistic understanding of disease translate into the rapid development and testing of targeted treatments that are safer and more effective than traditional agents for long-term disease control.

Dermatologists who want to explore current disease understanding and treatment and future treatments for

inflammatory skin diseases and the rationale for their use can find a comprehensive overview in Friday’s single symposium, “Inflammatory Skin Diseases: The Translational Revolution” that will feature some of the world’s leading experts in these diseases.

While conventional treatments may be effective to improve symptoms, they either harbor significant side effects — such as the risk of permanent kidney damage associated with more than one year of

continuous use of cyclosporine — or are not feasible for many, such as phototherapy. The arrival of new agents that can realistically offer the prospect of long-term disease control is a clinical revolution for treating dermatologists and for their patients.

“I’m excited about “Melanoma: The Future is Now.” It features my melanoma idols such as Dr. Suephy Chen, Dr. Darrell Rigel, and Dr. Susan Swetter. With the latest innovation in melanoma diagnostics and genomic profiling, it is important for us to selectively bring relevant testing/counseling to patient care.”

Shasa Hu, MDMiami

I appreciate the networking. I am able to meet with collaborators for research projects, participate in committee meetings, and catch-up with colleagues. Additionally, the talks on cutaneous oncology, particularly on high-risk squamous cell carcinoma are cutting edge and very apropos to my clinical practice.

David R. Carr, MDColumbus

“I am excited to learn about novel therapies for difficult to treat dermatologic diseases. As a resident, learning new treatment modalities from leading innovators aids me in confidently shaping my own methods of clinical practice. I hope to gain insights and direction from mentors who share my interest in dermatologic oncologic surgery!”

Atieh Jibbe, MDKansas City, Kansas

What are you excited to learn or see at the 2019 AAD Annual Meeting?

WATER COOLER

Biologic treatments are producing amazing results. The next step is targeted small molecule oral agents that are similarly effective in the real world.

Psoriasis Atopic dermatitis Alopecia areata Vitiligo Hidradenitis suppurativa

“Inflammatory Skin Diseases: The Translational Revolution” (S011)Friday, 1-4 p.m.Ballroom B

Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936-1080 © 2019 Novartis 1/19 T-COS-1362218

Discover theComplete

Cosentyx ApproachBooth #3021

These Industry Expert Sessions are promotional activities and are not approved for continuing education credit. The content of these sessions and opinions expressed by presenters are those of the Presenting Company or presenters and do not represent an endorsement by, nor imply that the products have been evaluated or approved by the

American Academy of Dermatology.

Novartis acts in accordance with the PhRMA Code on Interactions With Health Care Professionals. The PhRMA Code states that inclusion of a health care professional’s spouse or guest at an educational program is not appropriate. Your support of these ethical guidelines will help to ensure a high quality learning environment for all

participating health care professionals. Thank you.

Francisco A. Kerdel, MD, MBBS, BSc

Presented by:

Saturday, March 2, 201911:00 am – 11:45 am Program


Washington, DCPlease arrive at 10:45 am to register



Ben Lockshin, MD, FAAD

Presented by:

Friday, March 1, 20192:45 pm – 3:30 pm Program


Washington, DCPlease arrive at 2:30 pm to register



Hear Expert Insights at Two Unique Educational Sessions

Join us for these exciting events at this year’s AAD Annual Meeting!


PP-A1D-USA-1788 © 2019 Pfizer Inc. All rights reserved. Printed in USA/January 2019

Friday, March 1, 2019 • 1:30 pm – 2:15 pm • Industry Expert Theater, AAD Exhibit Floor

Please join us for a non-CME program presented by

Refreshments will be provided

This Industry Expert Session is a promotional activity and is not approved for continuing education credit. The content of this session and opinions expressed by presenters are those of the Presenting Company or presenters and do not represent an endorsement by, nor imply that the products have been evaluated or approved by the American Academy of Dermatology.

Notice: This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit their ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this or any Pfizer event. Your attendance will be considered confirmation to Pfizer that you have obtained any necessary approvals to attend this event.

State Laws and Pfizer Disclosures: The cost of meals and refreshments provided to US licensed Healthcare Professionals attending this Pfizer-sponsored program will be subject to public disclosure on www.pfizer.com as part of Pfizer’s Healthcare Professional Disclosure policies, and may also be subject to disclosure by state governmental authorities pursuant to your state law and applicable federal law such as the National Physician Payment Transparency Program (otherwise known as “Sunshine”). Pfizer’s disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. If you are licensed to practice in Minnesota or Vermont, we are prohibited from providing you any meals and/or refreshments due to your state limitation on meals, gifts or other items of value to HCPs and ask that you do not partake in the hospitality provided.

Learn About a Topical Option for Mild-to-Moderate Atopic Dermatitis

in Patients 2 Years and Older

Emily M. Becker, MD Sonterra Dermatology Driscoll Children’s Hospital Assistant Clinical Professor in Dermatology at University of Texas Health Science Center San Antonio, Texas

Download the new AAD Meeting Mobile AppFind the most up-to-date information at the AAD Meeting Mobile App. The app’s real-time functionality is easy to navigate and includes countless features, including the following:

Session scheduleList of sessions by day, type, category, and speaker. Bookmark sessions you like, take notes, or access session handouts.

ExhibitorsView the exhibit hall floor plan and search by name or category.Interactive maps. Explore floor plans for session rooms, events, and other areas.

EventsFind details on specific events, such as Council, Committee, or Task Force meetings, Affiliate and Reunion Groups, Industry Expert Sessions, and Industry Non-CME (INC) Programs.

Audience participationAccess Audience Response System sessions and provide feedback via your mobile device.

E-postersAccess e-posters and search by author, title, category, keyword, or poster number.

Vote Cast your ballot for AAD leadership.

NetworkFind and message colleagues to connect or stay in touch. Download the AAD Meeting Mobile App from the App Store or on Google Play. Search “AAD Meetings.” Or, visit www.aad.org/mobile. For platforms other than iOP or Android, there will be a mobile website with limited functionality. Assistance is available at the Walter E. Washington Convention Center in The Connection, Hall D.

Eat, meet, and network at the AAD Food Court

11 a.m.-2:30 p.m. Friday, Saturday, and Sunday.AAD Exhibit Floor located at the back of Hall C

International food stands offering a variety of healthy and delicious options. Ample seating available. Cash or credit accepted.

FAQs

Schedule Exhibitors

Maps

Speakers

CME/Evaluations

Event Listing SearchAudience Response

2019 AAD Annual MeetingWashington, D.C. • March 1–5, 2019

TARGET AUDIENCEThe educational design of this activity addresses the needs of dermatologists, clinical immunologists, and other clinicians involved in the treatment and management of patients with pustular psoriasis.

EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:• Describe the genetic and pathophysiologic

mechanisms that contribute to the development of pustular psoriasis including factors that have informed the development of new therapies

• Comprehensively assess patients with suspected pustular psoriasis based on clinical manifestations, diagnostic criteria, and disease severity

• Describe the mechanistic rationales and clinical evidence for current and emerging biologic therapies for the treatment of generalized pustular psoriasis and palmoplantar pustulosis

• Individualize therapeutic regimens for pustular psoriasis, with a focus on generalized disease subtypes and palmoplantar pustulosis

PROGRAM AGENDA7:00–7:10 Preactivity Questionnaire and

Faculty Introductions 7:10–7:30 Introduction to Pustular Psoriasis

Pathophysiology 7:30–7:50 Evaluating Patients With

Generalized Pustular Psoriasis or Palmoplantar Pustulosis

7:50–8:20 Evolving Therapeutic Approaches for Patients With Pustular Psoriasis

8:20–8:40 Case Study Discussion: Prerecorded Patient Examples

8:40–9:00 Postactivity Questionnaire and Q&A Session

AMERICANS WITH DISABILITIES ACT Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Christa Master prior to the live event at [email protected] program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee. This program does not qualify for continuing medical education (CME) credit.

PROGRAM OVERVIEWPustular psoriasis is a relatively rare form of psoriasis and has historically been classified into generalized and localized forms of the disease.1 Generalized pustular psoriasis is characterized by widespread sterile pustules on erythematous skin, recurrent fever, and systemic flushing and malaise.1,2 Palmoplantar pustulosis, a localized form, is characterized by erythema, pruritis, burning, and pain on the palms of the hands and soles of the feet. Recent evidence suggests that IL36RN mutations are the most common genetic aberration linked to pustular psoriasis, with the allelic frequency distinguishing generalized pustular psoriasis from palmoplantar pustulosis; the former shows a 4 to 1 increase versus the latter.3 Whether pustular psoriasis presents as localized or generalized, patients are subject to significant health risks and poor quality of life outcomes due to both skin and systemic manifestations. Patients may be subject to delays in diagnosis, in part because the disease states are relatively rare and there are little solid epidemiologic data.4 Dermatologists are faced with limited guidance on selecting therapies for patients with any of the pustular psoriasis subtypes.1 Biologic agents for pustular psoriasis and palmoplantar pustulosis are being examined in clinical trials. These include some biologics approved for psoriasis as well as agents with novel therapeutic targets, such as an anti-interleukin (IL)-36 receptor antibody.5 This Clinical Issues symposium will use both lecture and faculty discussion among leading dermatology experts to explore many of these issues, with an emphasis on evolving diagnostic and management strategies for generalized pustular psoriasis and palmoplantar pustulosis.

REFERENCES1. Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular

psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279-288.

2. Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235-1270.

3. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2018. [Epub ahead of print.]

4. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144.

5. Bachelez H, Choon S, Marrakchi S, et al. Efficacy and safety of BI 655130, an anti-interleukin-36 receptor antibody, in patients with acute generalized pustular psoriasis. Abstract D3T01.1E. EADV Congress; September 12-16, 2018; Paris, France.

This activity is jointly provided by Clinical and Patient Educators Association (CPEA) and Integritas Communications.

This activity is supported by an independent educational grant from Boehringer Ingelheim.

There is no registration fee for attending this program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Jeffrey J. Crowley, MD, FAADBakersfield Dermatology and Skin Cancer Medical Group

Bakersfield, California

Neil J. Korman, MD, PhDProfessor of Dermatology Department of Dermatology Case Western Reserve University Director, Clinical Trials Unit Clinical DirectorMurdough Family Center for Psoriasis University Hospitals Cleveland Medical Center

Cleveland, Ohio

Abby S. Van Voorhees, MDChair, Department of Dermatology Eastern Virginia Medical School Norfolk, Virginia

Jeffrey J. CrowleyBakersfield Dermatology and Skin Cancer Medical Group


Neil J. KormanProfessor of Dermatology Department of Dermatology Case Western Reserve University

Abby S. Van VoorheesChair, Department of Dermatology Eastern Virginia Medical School Norfolk, Virginia

2019 BI PSORIASIS NewsAd R1.indd 1 1/29/19 3:53 PM

TARGET AUDIENCEThe educational design of this activity addresses the needs of dermatologists, clinical immunologists, and other clinicians involved in the treatment and management of patients with pustular psoriasis.

EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:• Describe the genetic and pathophysiologic

mechanisms that contribute to the development of pustular psoriasis including factors that have informed the development of new therapies

• Comprehensively assess patients with suspected pustular psoriasis based on clinical manifestations, diagnostic criteria, and disease severity

• Describe the mechanistic rationales and clinical evidence for current and emerging biologic therapies for the treatment of generalized pustular psoriasis and palmoplantar pustulosis

• Individualize therapeutic regimens for pustular psoriasis, with a focus on generalized disease subtypes and palmoplantar pustulosis

PROGRAM AGENDA7:00–7:10 Preactivity Questionnaire and

Faculty Introductions 7:10–7:30 Introduction to Pustular Psoriasis

Pathophysiology 7:30–7:50 Evaluating Patients With

Generalized Pustular Psoriasis or Palmoplantar Pustulosis

7:50–8:20 Evolving Therapeutic Approaches for Patients With Pustular Psoriasis

8:20–8:40 Case Study Discussion: Prerecorded Patient Examples

8:40–9:00 Postactivity Questionnaire and Q&A Session

AMERICANS WITH DISABILITIES ACT Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Christa Master prior to the live event at [email protected] program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee. This program does not qualify for continuing medical education (CME) credit.

PROGRAM OVERVIEWPustular psoriasis is a relatively rare form of psoriasis and has historically been classified into generalized and localized forms of the disease.1 Generalized pustular psoriasis is characterized by widespread sterile pustules on erythematous skin, recurrent fever, and systemic flushing and malaise.1,2 Palmoplantar pustulosis, a localized form, is characterized by erythema, pruritis, burning, and pain on the palms of the hands and soles of the feet. Recent evidence suggests that IL36RN mutations are the most common genetic aberration linked to pustular psoriasis, with the allelic frequency distinguishing generalized pustular psoriasis from palmoplantar pustulosis; the former shows a 4 to 1 increase versus the latter.3 Whether pustular psoriasis presents as localized or generalized, patients are subject to significant health risks and poor quality of life outcomes due to both skin and systemic manifestations. Patients may be subject to delays in diagnosis, in part because the disease states are relatively rare and there are little solid epidemiologic data.4 Dermatologists are faced with limited guidance on selecting therapies for patients with any of the pustular psoriasis subtypes.1 Biologic agents for pustular psoriasis and palmoplantar pustulosis are being examined in clinical trials. These include some biologics approved for psoriasis as well as agents with novel therapeutic targets, such as an anti-interleukin (IL)-36 receptor antibody.5 This Clinical Issues symposium will use both lecture and faculty discussion among leading dermatology experts to explore many of these issues, with an emphasis on evolving diagnostic and management strategies for generalized pustular psoriasis and palmoplantar pustulosis.

REFERENCES1. Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular

psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279-288.

2. Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235-1270.

3. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2018. [Epub ahead of print.]

4. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144.

5. Bachelez H, Choon S, Marrakchi S, et al. Efficacy and safety of BI 655130, an anti-interleukin-36 receptor antibody, in patients with acute generalized pustular psoriasis. Abstract D3T01.1E. EADV Congress; September 12-16, 2018; Paris, France.

This activity is jointly provided by Clinical and Patient Educators Association (CPEA) and Integritas Communications.

This activity is supported by an independent educational grant from Boehringer Ingelheim.

There is no registration fee for attending this program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Jeffrey J. Crowley, MD, FAADBakersfield Dermatology and Skin Cancer Medical Group


Neil J. Korman, MD, PhDProfessor of Dermatology Department of Dermatology Case Western Reserve University Director, Clinical Trials Unit Clinical DirectorMurdough Family Center for Psoriasis University Hospitals Cleveland Medical Center

Cleveland, Ohio

Abby S. Van Voorhees, MDChair, Department of Dermatology Eastern Virginia Medical School Norfolk, Virginia

Jeffrey J. CrowleyBakersfield Dermatology and Skin Cancer Medical Group


Neil J. KormanProfessor of Dermatology Department of Dermatology Case Western Reserve University

Abby S. Van VoorheesChair, Department of Dermatology Eastern Virginia Medical School Norfolk, Virginia

2019 BI PSORIASIS NewsAd R1.indd 1 1/29/19 3:53 PM

PREPARED BY FCB

Job #: 11101394Releasing as: PDFx1a Production: Debi Post X2844

Colors: 4C AD: [email protected]

Client: Dermira Bleed: 21" x 14.25" AE: Tyler Byrne

Product: Qbrexza Finished Size: 10.375" x 14" Producer: Hakeem Williams

Client Code: PM-US-QBR-0349 Trim/Final: 20.75" x 14" QC: L.Powell

Date: February 5, 2019 4:08 PM Live/Safety: 20.25" x 13.50"h Digital Artist: tp, VA, tp, VA, tp, VA, lp

Proof: M7 Add’l Info: .25 gutter each sideFR Spellcheck: P. Stoopack

Path: PrePress:Dermira:11101394:11101394_AAD_Ann_Mtg_News_M7

4C AAD Annual Meeting News Daily

For patients aged 9 years and older with primary axillary hyperhidrosis

Once-daily QBREXZA is the first and only FDA-approved, topical anticholinergic cloth towelette1

©2019 Dermira, Inc. All rights reserved. PM-US-QBR-0349 01/2019

Reference: 1. QBREXZA™ (glycopyrronium) cloth prescribing information, Dermira.

QBREXZA.com/HCP

Discover

Visit Booth #415

March 2, 2019 at 2:45 PM | Industry Experts Theater | Booth #002

Come Join Our Industry Expert Session and Raise the Bar for Your Patients With Primary Axillary Hyperhidrosis

INDICATION QBREXZATM (glycopyrronium) cloth is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION Contraindications: QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).

WARNINGS AND PRECAUTIONSWorsening of Urinary Retention: QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

ADVERSE REACTIONSThe most common adverse reactions seen in ≥2% of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat

(2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.

DRUG INTERACTIONSAnticholinergics: Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

INSTRUCTIONS FOR ADMINISTERING QBREXZAInstruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

USE IN SPECIFIC POPULATIONSPregnancy: There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Lactation: There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

Renal Impairment: The elimination of glycopyrronium is severely impaired in patients with renal failure.

Please see Brief Summary of Full Prescribing Information on adjacent page.

QBREXZATM (glycopyrronium) cloth, 2.4%, for topical useThe following is a Brief Summary; refer to Full Prescribing Information for complete product information.

1 INDICATIONS AND USAGEQBREXZA is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

2 DOSAGE AND ADMINISTRATION

For topical use only.

QBREXZA is for topical use in the underarm area only and not for use in other body areas.

QBREXZA is administered by a single-use pre-moistened cloth packaged in individual pouches. QBREXZA should be applied to clean dry skin on the underarm areas only. QBREXZA should not be used more frequently than once every 24 hours.

Tear open the pouch and pull out the cloth, unfold the cloth, and wipe it across one entire underarm once. Using the same cloth, wipe the other underarm once. A single cloth should be used to apply QBREXZA to both underarms.

Wash hands immediately with soap and water after applying and discarding the QBREXZA cloth. QBREXZA may cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes. Avoid transfer of QBREXZA to the periocular area [see Warnings and Precautions (5.3)].

Do not apply QBREXZA to broken skin. Avoid using QBREXZA with occlusive dressings.

4 CONTRAINDICATIONS

QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g, glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).

5 WARNINGS AND PRECAUTIONS5.1 Worsening of Urinary Retention QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop.

Patients with a history of urinary retention were not included in the clinical studies.

5.2 Control of Body Temperature In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

5.3 Operating Machinery or an AutomobileTransient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections • Worsening of Urinary Retention [see Warnings and Precautions (5.1)]

6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two double-blind, vehicle-controlled clinical trials (Trial 1 [NCT02530281] and Trial 2 [NCT02530294]) of 459 subjects treated with QBREXZA once daily and 232 treated with vehicle, subjects were 9 to 76 years of age, 47% male, and the percentages of White, Black (including African Americans), and Asian subjects were 82%, 12%, and 1%, respectively.

Table 1 summarizes the most frequent adverse reactions (≥2%) in subjects with primary axillary hyperhidrosis treated with QBREXZA.

Table 1: Adverse Reactions Occurring in ≥2% of Subjects

Adverse ReactionsQBREXZA (N=459)

n (%)

Vehicle (N=232)

n (%)

Dry mouth 111 (24.2%) 13 (5.6%)

Mydriasis 31 (6.8%) 0

Oropharyngeal pain 26 (5.7%) 3 (1.3%)

Headache 23 (5.0%) 5 (2.2%)

Urinary hesitation 16 (3.5%) 0

Vision blurred 16 (3.5%) 0

Nasal dryness 12 (2.6%) 1 (0.4%)

Dry throat 12 (2.6%) 0

Dry eye 11 (2.4%) 1 (0.4%)

Dry skin 10 (2.2%) 0

Constipation 9 (2.0%) 0

Table 2 shows the most frequently reported local skin reactions, which were relatively common in both the QBREXZA and vehicle groups.

Table 2: Local Skin Reactions

Local Skin ReactionsQBREXZA (N=454)a

n (%)

Vehicle (N=231) a

n (%)

Erythema 77 (17.0%) 39 (16.9%)

Burning/stinging 64 (14.1%) 39 (16.9%)

Pruritus 37 (8.1%) 14 (6.1%)

aPatients with a post-baseline local skin reaction assessment

In an open-label safety trial (NCT02553798), 564 subjects were treated for up to an additional 44 weeks after completing Trial 1 or Trial 2. Adverse reactions occurring at a frequency ≥2.0% were: dry mouth (16.9%), vision blurred (6.7%), nasopharyngitis (5.8%), mydriasis (5.3%), urinary hesitation (4.2%), nasal dryness (3.6%), dry eye (2.9%), pharyngitis (2.2%), and application site reactions (pain [6.4%], dermatitis [3.8%], pruritus [3.8%], rash [3.8%], erythema [2.4%]).

7 DRUG INTERACTIONS7.1 AnticholinergicsCoadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects [see Warnings and Precautions (5) and Adverse Reactions (6)]. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

8 USE IN SPECIFIC POPULATIONS8.1 PregnancyThere are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. In pregnant rats, daily oral administration of glycopyrrolate (glycopyrronium bromide) during organogenesis did not result in an increased incidence of gross external or visceral defects. When glycopyrrolate was administered intravenously to pregnant rabbits during organogenesis, no adverse effects on embryo-fetal development were seen. The available data do not support relevant comparisons of systemic glycopyrronium exposures achieved in the animal studies to exposures observed in humans after topical use of QBREXZA.

The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 LactationThere are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

8.4 Pediatric UseThe safety, effectiveness and pharmacokinetics of QBREXZA have been established in pediatric patients age 9 years and older for topical treatment of primary axillary hyperhidrosis. Use of QBREXZA in this age group is supported by evidence from two multicenter, randomized, double-blind, parallel-group, vehicle-controlled 4-week trials which included 34 pediatric subjects 9 years and older [see Adverse Reactions (6.1)]. The safety and effectiveness of QBREXZA have not been established in pediatric patients under 9 years of age.

8.5 Geriatric UseClinical trials of QBREXZA did not include sufficient numbers of subjects age 65 years and older to determine whether they respond differently from younger subjects.

8.6 Renal ImpairmentThe elimination of glycopyrronium is severely impaired in patients with renal failure.

10 OVERDOSAGE

Because glycopyrronium is a quaternary amine which does not easily cross the blood-brain barrier, symptoms of glycopyrronium overdosage are generally more peripheral in nature rather than central compared to other anticholinergic agents. Associated signs and symptoms related to excessive anticholinergic activity may include flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation and light sensitivity due to mydriasis.

In the case of overdose when symptoms are severe or life threatening, therapy may include:

• Managing per standard of care any acute conditions such as hyperthermia, coma, and/or seizures, as applicable, and managing any myoclonic or choreoathetoid movements which may lead to rhabdomyolysis in some cases of anticholinergic overdosage

• Managing severe urinary retention with catheterization if not spontaneously reversed within several hours

• Providing cardiovascular support and/or controlling arrhythmias

• Maintaining an open airway, providing ventilation as necessary

• Administering a quaternary ammonium anticholinesterase such as neostigmine to help alleviate severe and/or life threatening peripheral anticholinergic effects.

Topical overdosing of QBREXZA could result in an increased incidence or severity of local skin reactions. Administration of QBREXZA under occlusive conditions may result in an increase in anticholinergic effects, including dry mouth and urinary hesitation.

16.2 Storage and HandlingStore at room temperature 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature].

QBREXZA is flammable; keep away from heat or flame.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Worsening of Urinary Retention Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder). Instruct patients to discontinue use and consult a physician immediately should any of these signs or symptoms develop.

Control of Body Temperature (Risk of Overheating or Heat Illness) In the presence of high ambient temperature, heat illness due to decreased sweating can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile Transient blurred vision may occur with QBREXZA. If this occurs, instruct patients to contact their healthcare provider, discontinue use of QBREXZA and avoid operating a motor vehicle or other machinery, or performing hazardous work until symptoms resolve.

Instructions for Administering QBREXZA It is important for patients to understand how to correctly apply QBREXZA (see Patient Information).

• Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME.

• Using the same cloth, apply the medication to the other underarm, ONE TIME.

• Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

• Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

• Remind patients not to apply QBREXZA to other body areas or to broken skin. Instruct patients to avoid using QBREXZA with occlusive dressings.

• QBREXZA is flammable; avoid use near heat or flame.

Manufactured for:

Dermira, Inc. Menlo Park, CA 94025

Version 1, June 2018

PM-US-QBR-0029

S:20.25”

S:13.5”

T:20.75”

T:14”

B:21”

B:14.25”

F:10.375”

FS:9.875”

F:10.375”

FS:9.875”

11101394_AAD_Ann_Mtg_News_M7.indd 1 2/5/19 4:08 PM

PREPARED BY FCB

Job #: 11101394Releasing as: PDFx1a Production: Debi Post X2844

Colors: 4C AD: [email protected]

Client: Dermira Bleed: 21" x 14.25" AE: Tyler Byrne

Product: Qbrexza Finished Size: 10.375" x 14" Producer: Hakeem Williams

Client Code: PM-US-QBR-0349 Trim/Final: 20.75" x 14" QC: L.Powell

Date: February 5, 2019 4:08 PM Live/Safety: 20.25" x 13.50"h Digital Artist: tp, VA, tp, VA, tp, VA, lp

Proof: M7 Add’l Info: .25 gutter each sideFR Spellcheck: P. Stoopack

Path: PrePress:Dermira:11101394:11101394_AAD_Ann_Mtg_News_M7

4C AAD Annual Meeting News Daily

For patients aged 9 years and older with primary axillary hyperhidrosis

Once-daily QBREXZA is the first and only FDA-approved, topical anticholinergic cloth towelette1

©2019 Dermira, Inc. All rights reserved. PM-US-QBR-0349 01/2019

Reference: 1. QBREXZA™ (glycopyrronium) cloth prescribing information, Dermira.

QBREXZA.com/HCP

Discover

Visit Booth #415

March 2, 2019 at 2:45 PM | Industry Experts Theater | Booth #002

Come Join Our Industry Expert Session and Raise the Bar for Your Patients With Primary Axillary Hyperhidrosis

INDICATION QBREXZATM (glycopyrronium) cloth is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION Contraindications: QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).

WARNINGS AND PRECAUTIONSWorsening of Urinary Retention: QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

ADVERSE REACTIONSThe most common adverse reactions seen in ≥2% of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat

(2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.

DRUG INTERACTIONSAnticholinergics: Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

INSTRUCTIONS FOR ADMINISTERING QBREXZAInstruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

USE IN SPECIFIC POPULATIONSPregnancy: There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Lactation: There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

Renal Impairment: The elimination of glycopyrronium is severely impaired in patients with renal failure.

Please see Brief Summary of Full Prescribing Information on adjacent page.

QBREXZATM (glycopyrronium) cloth, 2.4%, for topical useThe following is a Brief Summary; refer to Full Prescribing Information for complete product information.

1 INDICATIONS AND USAGEQBREXZA is indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

2 DOSAGE AND ADMINISTRATION

For topical use only.

QBREXZA is for topical use in the underarm area only and not for use in other body areas.

QBREXZA is administered by a single-use pre-moistened cloth packaged in individual pouches. QBREXZA should be applied to clean dry skin on the underarm areas only. QBREXZA should not be used more frequently than once every 24 hours.

Tear open the pouch and pull out the cloth, unfold the cloth, and wipe it across one entire underarm once. Using the same cloth, wipe the other underarm once. A single cloth should be used to apply QBREXZA to both underarms.

Wash hands immediately with soap and water after applying and discarding the QBREXZA cloth. QBREXZA may cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes. Avoid transfer of QBREXZA to the periocular area [see Warnings and Precautions (5.3)].

Do not apply QBREXZA to broken skin. Avoid using QBREXZA with occlusive dressings.

4 CONTRAINDICATIONS

QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g, glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).

5 WARNINGS AND PRECAUTIONS5.1 Worsening of Urinary Retention QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop.

Patients with a history of urinary retention were not included in the clinical studies.

5.2 Control of Body Temperature In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

5.3 Operating Machinery or an AutomobileTransient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections • Worsening of Urinary Retention [see Warnings and Precautions (5.1)]

6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two double-blind, vehicle-controlled clinical trials (Trial 1 [NCT02530281] and Trial 2 [NCT02530294]) of 459 subjects treated with QBREXZA once daily and 232 treated with vehicle, subjects were 9 to 76 years of age, 47% male, and the percentages of White, Black (including African Americans), and Asian subjects were 82%, 12%, and 1%, respectively.

Table 1 summarizes the most frequent adverse reactions (≥2%) in subjects with primary axillary hyperhidrosis treated with QBREXZA.

Table 1: Adverse Reactions Occurring in ≥2% of Subjects

Adverse ReactionsQBREXZA (N=459)

n (%)

Vehicle (N=232)

n (%)

Dry mouth 111 (24.2%) 13 (5.6%)

Mydriasis 31 (6.8%) 0

Oropharyngeal pain 26 (5.7%) 3 (1.3%)

Headache 23 (5.0%) 5 (2.2%)

Urinary hesitation 16 (3.5%) 0

Vision blurred 16 (3.5%) 0

Nasal dryness 12 (2.6%) 1 (0.4%)

Dry throat 12 (2.6%) 0

Dry eye 11 (2.4%) 1 (0.4%)

Dry skin 10 (2.2%) 0

Constipation 9 (2.0%) 0

Table 2 shows the most frequently reported local skin reactions, which were relatively common in both the QBREXZA and vehicle groups.

Table 2: Local Skin Reactions

Local Skin ReactionsQBREXZA (N=454)a

n (%)

Vehicle (N=231) a

n (%)

Erythema 77 (17.0%) 39 (16.9%)

Burning/stinging 64 (14.1%) 39 (16.9%)

Pruritus 37 (8.1%) 14 (6.1%)

aPatients with a post-baseline local skin reaction assessment

In an open-label safety trial (NCT02553798), 564 subjects were treated for up to an additional 44 weeks after completing Trial 1 or Trial 2. Adverse reactions occurring at a frequency ≥2.0% were: dry mouth (16.9%), vision blurred (6.7%), nasopharyngitis (5.8%), mydriasis (5.3%), urinary hesitation (4.2%), nasal dryness (3.6%), dry eye (2.9%), pharyngitis (2.2%), and application site reactions (pain [6.4%], dermatitis [3.8%], pruritus [3.8%], rash [3.8%], erythema [2.4%]).

7 DRUG INTERACTIONS7.1 AnticholinergicsCoadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects [see Warnings and Precautions (5) and Adverse Reactions (6)]. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

8 USE IN SPECIFIC POPULATIONS8.1 PregnancyThere are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. In pregnant rats, daily oral administration of glycopyrrolate (glycopyrronium bromide) during organogenesis did not result in an increased incidence of gross external or visceral defects. When glycopyrrolate was administered intravenously to pregnant rabbits during organogenesis, no adverse effects on embryo-fetal development were seen. The available data do not support relevant comparisons of systemic glycopyrronium exposures achieved in the animal studies to exposures observed in humans after topical use of QBREXZA.

The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 LactationThere are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

8.4 Pediatric UseThe safety, effectiveness and pharmacokinetics of QBREXZA have been established in pediatric patients age 9 years and older for topical treatment of primary axillary hyperhidrosis. Use of QBREXZA in this age group is supported by evidence from two multicenter, randomized, double-blind, parallel-group, vehicle-controlled 4-week trials which included 34 pediatric subjects 9 years and older [see Adverse Reactions (6.1)]. The safety and effectiveness of QBREXZA have not been established in pediatric patients under 9 years of age.

8.5 Geriatric UseClinical trials of QBREXZA did not include sufficient numbers of subjects age 65 years and older to determine whether they respond differently from younger subjects.

8.6 Renal ImpairmentThe elimination of glycopyrronium is severely impaired in patients with renal failure.

10 OVERDOSAGE

Because glycopyrronium is a quaternary amine which does not easily cross the blood-brain barrier, symptoms of glycopyrronium overdosage are generally more peripheral in nature rather than central compared to other anticholinergic agents. Associated signs and symptoms related to excessive anticholinergic activity may include flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation and light sensitivity due to mydriasis.

In the case of overdose when symptoms are severe or life threatening, therapy may include:

• Managing per standard of care any acute conditions such as hyperthermia, coma, and/or seizures, as applicable, and managing any myoclonic or choreoathetoid movements which may lead to rhabdomyolysis in some cases of anticholinergic overdosage

• Managing severe urinary retention with catheterization if not spontaneously reversed within several hours

• Providing cardiovascular support and/or controlling arrhythmias

• Maintaining an open airway, providing ventilation as necessary

• Administering a quaternary ammonium anticholinesterase such as neostigmine to help alleviate severe and/or life threatening peripheral anticholinergic effects.

Topical overdosing of QBREXZA could result in an increased incidence or severity of local skin reactions. Administration of QBREXZA under occlusive conditions may result in an increase in anticholinergic effects, including dry mouth and urinary hesitation.

16.2 Storage and HandlingStore at room temperature 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature].

QBREXZA is flammable; keep away from heat or flame.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Worsening of Urinary Retention Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder). Instruct patients to discontinue use and consult a physician immediately should any of these signs or symptoms develop.

Control of Body Temperature (Risk of Overheating or Heat Illness) In the presence of high ambient temperature, heat illness due to decreased sweating can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile Transient blurred vision may occur with QBREXZA. If this occurs, instruct patients to contact their healthcare provider, discontinue use of QBREXZA and avoid operating a motor vehicle or other machinery, or performing hazardous work until symptoms resolve.

Instructions for Administering QBREXZA It is important for patients to understand how to correctly apply QBREXZA (see Patient Information).

• Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME.

• Using the same cloth, apply the medication to the other underarm, ONE TIME.

• Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

• Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

• Remind patients not to apply QBREXZA to other body areas or to broken skin. Instruct patients to avoid using QBREXZA with occlusive dressings.

• QBREXZA is flammable; avoid use near heat or flame.

Manufactured for:

Dermira, Inc. Menlo Park, CA 94025

Version 1, June 2018

PM-US-QBR-0029

S:20.25”S:13.5”

T:20.75”T:14”

B:21”B:14.25”

F:10.375”

FS:9.875”

F:10.375”

FS:9.875”

11101394_AAD_Ann_Mtg_News_M7.indd 1 2/5/19 4:08 PM


Brought to you byBe the first to know. Find out more at

www.SkyriziHCP.com

©2019 AbbVie Inc. North Chicago, IL 60064 US-RISN-180097 March 2019 Printed in U.S.A.

SOMETHING NEWIS APPROACHINGIS APPROACHING

Brought to you byBe the first to know. Find out more atBe the first to know. Find out more atBe the first to know. Find out more at

www.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.com

EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111

US-RISN-180097_M03_Map_Premium_Coming Soon Ad.indd 1 1/15/19 12:59 PM

Shaping AI for dermatologyN ew technologies and

techniques are changing melanoma diagnosis and

treatment. Noninvasive biopsies, augmented intelligence (AI), novel detection strategies, and other technologies that sound like clinical dreams are already changing practice. This technological shift is as important as the paradigm shifts that followed the introduction of Mohs surgery and immunohistochemical staining in dermatology and skin cancer.

“Melanoma is the most deadly cancer in the sense that more life years are lost to it than to any other cancer,” said Eric Tkaczyk, MD, PhD, assistant professor of dermatology and of biomedical engineering at Vanderbilt University and director of the Vanderbilt Cutaneous Imaging Clinic. “Anyone can get it at any age. It is the flag that the entire community of dermatology gathers around because early diagnosis saves so many lives.”

Dr. Tkaczyk is among the presenters at Friday’s “Melanoma: The Future Is Now.” On Saturday, the session, “Predicting the Future: AI, Machine Learning, and Dermatology” adds more perspective.

Current data suggests AI is equal or better at diagnosing melanoma than most dermatologists. In 2018,

the third Grand Challenge, sponsored by the International Skin Imaging Collaboration unveiled algorithms that can diagnose melanoma and six other types of skin cancers using skin images more accurately than 97% of expert dermatologist readers.

But don’t worry. More patients will be driven to see dermatologists“The reality is that the more computers can diagnose, the more people will be driven to see dermatologists, not fewer. The role of the dermatologist may change, but rather than being usurped, our role will be augmented,” said Allan C. Halpern, MD, chief of dermatology at Memorial Sloan Kettering Cancer Center. He is president of the ISIC.

Dermatologists who worry they may be replaced by apps should agonize less about the perceived threat and consider the opportunities that AI presents.

“We should embrace AI and help shape the changing environment, mold it in ways that benefit our patients and improve treatment,” said Roger S. Ho, MD, MS, MPH, assistant professor of dermatology at the Ronald O. Perelman Department of Dermatology at New York University School of Medicine.

One of the ways to shape AI is to help train dermatology algorithms so they can diagnose more accurately in more skin types. The problem is limited data sets.

What can the data tell dermatologists?“You use a data set to teach the algorithm what is right and what is wrong, what is melanoma and what is not melanoma. If the data set is biased, say the majority of tumors are in light skin, the algorithm may miss potentially life-threatening tumors when presented with darker skin types,” said Adewole Adamson, MD, MPP, assistant professor of dermatology at Dell Medical School at the University of Texas at Austin.

AI engineers may not know enough about dermatology to recognize or remedy the problem. That’s where dermatologists help, says Clara Curiel-Lewandrowski, MD, professor of medicine and dermatology at the University

of Arizona, director of the University Cutaneous Oncology Program, clinical director of the Skin Cancer Institute, and Alan and Janice Levin endowed chair in Cancer Research.

Responsibility lies with dermatologists“As dermatologists we have the responsibility to lead the development and adoption of AI-based technologies into our field. It is up to us to transform the implementation of AI into an opportunity, not a threat, and to ultimately augment our clinical practice,” Dr. Curiel-Lewandrowski said.

“Melanoma: The Future is Now” (S001)Friday, 9 a.m.-12 p.m.Room 204A

“Predicting the Future: AI, Machine Learning and Dermatology” (D004)Saturday, 3:30-5:30 p.m.Room 101

New imaging technologiesNew technologies and techniques are changing melanoma diagnosis and treatment.

Confocal microscopy: Reflectance confocal microscopy uses laser illumination to visualize cellular details of the superficial dermis and epidermis in real time.

Photoacoustics: A combination of sound and light frequencies.

Raman spectroscopy: Lesion identification based on its molecular makeup.

Molecular assays: Determining which genes are upregulated to predict tumor behavior via DecisionDx-Melanoma assays mRNA within a tumor.

Augmented intelligence: SkinVision is among the early commercial apps to diagnose skin cancer.

We should embrace AI and help shape the changing environment, mold it in ways that benefit our patients and improve treatment.

Roger S. Ho, MD, MS, MPH

Brought to you byBe the first to know. Find out more at

www.SkyriziHCP.com


SOMETHING NEWIS APPROACHINGIS APPROACHING

Brought to you byBe the first to know. Find out more atBe the first to know. Find out more atBe the first to know. Find out more at

www.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.comwww.SkyriziHCP.com

EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111EXPERIENCE THE SKY AT BOOTH #2111

US-RISN-180097_M03_Map_Premium_Coming Soon Ad.indd 1 1/15/19 12:59 PM


001

1000 1001

1002 1003

1004 1005

1009

1019

1021

1037

1041

1043

1045

1047

1100 1101

1103

1105

1109

1118 1119

1123

1127

1129

1136 1137

1138

1140 1141

1142

1144

1200 1201

1204

1209

1217

1218

1222 1223

1224

1236 1237

1240

1301

1311

1316

1319

1325

1337

1343

1401

1403

1409

1418 1419

1437

1500 1501

1504

1509

1515

1537

1545

1609

1645

1701

1709

1719

1721

1723

1727

1737

1801

1809

1811

1813

1815

1818 1819

1822 1823

1837

1845

1908 1909

1910

1912

1916 1917

1923

1945

200 2001

2005

2009

201

2019

202

2025

2037

204

2047

208 209

210

2100 2101

2104

2111

2118

212

2137

214

2146 2147

2153

2159

216

2163

218 219

220

2201

221

222 223

2247

2251

2253

2255

2257

2258

226

2261

2262

227

2301

2305

2307

2319

2325

2337

2345

2346 2347

2350

2354 2355

2357

2361

2400 2401

2406

2418

2423

2437

2444 2445

2451

2453

2454 2455

2457

2458

2461

2545

2550

2554 2555

2561

2601

2619

2627

2637

2645

2655

2660

2719

2725

2737

2751

2761

2819

2861

2901

2909

2919

2925

2937

2943

2955

2959

2963

3001301

3015

3021

303

3037

3054 3055

3058

3060 3061

3062

307

313

3154 3155

3157

3159

3160 3161

3163

318 3219

3227

3237

3247

3254 3255

3256 3257

3260 3261

327

3301

3309

3315

3321

3337 3345

3346

3351

3354

3356 3357

3361

3401

3411

3421

3450 3451

3454

3457

3459

3555

3556 3557

3558

3560 3561

3563

3600

3621

3625

3637

3645

3654

3658

3661

3662

3720 3721

3761

3801

3811

3819

3820

3825

3837

3845

3855

3910 3911

3913

3917

3919

3945

3947

3951

3953

3955

3957

3961

400 4001

4005

4009

401

4010 4011

4012 4013

4014

4016 4017

4018

4023

403

4037

4044

4046

405

4050

4052 4053

4054 4055

406

4061

407

408 409

4100 4101

4103

4104 4105

4107

4108

4110 4111

4119

4125

415

4152

4155

4156 4157

4159

4161

4163

4200 4201

4202

4206

4208

4210 4211

4221

4223

4225

4227

4229

425

426

428

4301

4309

4313

4315

4317

4319

4320 4321

4322

4324

4326 4327

4328

4337

4341

4343

4347

4405

4407

4408

4411

4412

4414

4416

4418 4419

4420

4422 4423

4429

4436 4437

4438

4440 4441

4442 4443

4444

4446 4447

4448

500 501

502

502650285030

506 507

508

512651285130

519

522652285230

532653285330

542654285430

552655285530

562656285630

572657285730

582658285830

592659285930

601

602660286030

609

615

619

625

708 709

710 711

712 713

715

719

736 737

739

740 741

742

744 745

746

801

807

808

814

819

825

829

836 837

840 841

901

903

905

911

919

924 925

928

936 937

938

940

943

Hall C Entrance

IndustryExpertsTheater

AAD Food Court

002

Hall B Entrance Hall A Entrance

#

3Gen, Inc./DermLite ................................... 1701

5CC (5-Continent-Congress) .......................... 615

A

AAD Industry Experts Theater........................... 2

Abacosm LTD ............................................. 4347

AbbVie ...............2101, 2111, 5626, 5628, 5630, 5726, 5728, 5730, 5830

Accurate Manufacturing Inc .......................... 428

AccuTec Blades ........................................... 2355

AccuVein .................................................... 1047

Aclaris Therapeutics, Inc ............................... 601

Acuderm..................................................... 2337

AD Surgical ................................................ 4005

Adult & Pediatric Dermatology, PC .............. 4437

Advalight ...................................................... 710

Advanced Dermatology & Cosmetic Surgery ................................ 3919

Advanced MD, Inc. ..................................... 2350

Aerolase ...................................................... 1917

Aesthetics Biomedical ................................. 4206

Allergan .................................. 1909, 2401, 5030

Alma Lasers ................................................ 2009

ALMIRALL ................................................. 4211

Alphaeon Corporation ................................. 2255

AMA-Meditime ........................................... 2257

American Academy of Dermatology ............ 4055

American Board of Dermatology ................. 2319

American Society for Dermatologic Surgery ........................ 1908

American Society for Mohs Surgery ............. 3346

Amgen, Inc. ................................................ 3637

AMP Medical Products, LLC.......................... 715

Amryt Pharma ............................................ 4422

Anne Arundel Dermatology, P.A. ................. 4225

Anthony Products/Gio Pelle ........................ 1100

Aptar Pharma ............................................. 4103

Aquavit Pharmaceuticals, Inc. ..................... 1003

Ascentium Capital LLC ............................... 1222

Asclepion Laser Technologies ...................... 1709

Aurora Diagnostics ....................................... 425

Australasian College of Dermatologists ......... 938

B

Baitella AG ................................................. 2253

Bank of America Practice Solutions ............. 2047

Beiersdorf, Inc. ........................................... 2737

Beijing Sincoheren S&T Development Co., LTD ................................................. 1138

Beijing Syntech Laser Co., Ltd. ...................... 736

Bellaire Industry/Mesopen .......................... 1005

Benev Company Inc. ......................... 1109, 1204

Berkshire Health Systems ............................. 936

Biodermis ................................................... 1319

Biofrontera, Inc. ............................................ 209

Biopelle, Inc ............................................... 3237

BioPharmX ................................................... 502

Biorasi ........................................................ 2455

bioskin GmbH ............................................ 3450

BirdEye ......................................................... 406

Blaine Labs, Inc. ......................................... 3457

BLUECORE COMPANY CO., LTD ................ 301

Boehringer Ingelheim Pharmaceuticals, Inc ..................... 4327, 5128

Boiron ........................................................ 3155

Bovie Medical ............................................. 4009

brandMD Skin Care ...................................... 937

Brazilian Society for Dermatological Surgery ................................................... 2445

Brymill Cryogenic Systems .......................... 2400

BTL ............................................................ 1009

C

Cabana Life ................................................... 814

Caliber Imaging & Diagnostics .................... 2019

Candela ...................................................... 2137

Canfield Scientific ....................................... 1923

Cantabria Labs ............................................ 3261

Capillus, LLC ................................................ 943

CareCredit .................................................. 1509

Cartessa Aesthetics, LLC ............................... 741

Castle Biosciences, Inc. ............................... 3654

Celgene Corporation ......................... 3421, 5928

Certain Dri ................................................. 4412

Chase Merchant Services ............................... 212

CheckedUP................................................. 4423

Chemistry Rx .............................................. 2959

Chemotechnique Diagnostics/ Dormer Laboratories ............................... 2955

Cherry Imaging .......................................... 1813

CLASSYS ...................................................... 201

Cleure ........................................................ 4313

Clinical Resolution Lab, Inc. ........................ 1240

CLN Skin Care (TopMD Skin Care) ............. 4221

CNH Pillow, Inc. ......................................... 1910

Coalition of Skin Diseases ........................... 3913

Cobalt Medical Supply, Inc. ......................... 3451

cocoon medical ............................................. 307

CoLabs Intl Corp ......................................... 2247

Collagen P.I.N. ............................................ 2153

Compulink Healthcare Solutions ................. 4018

COOLA Suncare ......................................... 3260

Coolibar, Sun Protection You Wear .............. 3054

Corrona LLC ............................................... 3356

Cortex Technology Aps ................................ 1136

CRC Press - Taylor & Francis ....................... 1811

Crown Laboratories, Inc. ............................. 3315

Crystal Clear Digital Marketing ................... 2963

CureMD Healthcare ...................................... 825

Cutanea Life Sciences, Inc ..................... 223, 313

Cutera ........................................................ 1501

Cutis & Cosmetic Dermatology ................... 1723

Cutis Diagnostics ........................................ 4011

Cynosure .................................................... 1801

D

Daavlin ....................................................... 3837

Dartmouth-Hitchcock ................................... 746

DefenAge ..................................................... 508

DEKA Medical ............................................ 1609

Delasco ....................................................... 2627

Derma Faith, LLC ....................................... 3160

DermaSculpt -CosmoFrance ........................ 4111

Dermasensa Laboratories, Inc. .................... 4343

DermaSweep .............................................. 1119

Dermatologic Cosmetic Laboratories ........... 2645

Dermatologist, The ..................................... 3911

Dermatology Advisor .................................. 2251

Dermatology Foundation ............................ 2001

Dermatology News ...................................... 1721

Dermatology Times ...................................... 303

Dermira, Inc. ...................................... 415, 5926

DermoScan Inc. .......................................... 4155

Dermpath Diagnostics ................................ 3625

Dermpath Lab of Central States ................... 1818

▼To Hall D

(shown at right)

Exhi

bit

Hal

l Hou

rs FRIDAY: 10 a.m.-5 p.m.Unopposed hours: 12-1 p.m.

SATURDAY: 10 a.m.-5 p.m.Unopposed hours: 12-1 p.m.

SUNDAY: 10 a.m.-3 p.m.Unopposed hours: 12-1 p.m.

Map sponsored by AbbVie

Data current as of Jan. 10, 2019.

DERMATOLOGY WORLD MEETING NEWS • FRIDAY • MARCH 1, 2019 15

001

1000 1001

1002 1003

1004 1005

1009

1019

1021

1037

1041

1043

1045

1047

1100 1101

1103

1105

1109

1118 1119

1123

1127

1129

1136 1137

1138

1140 1141

1142

1144

1200 1201

1204

1209

1217

1218

1222 1223

1224

1236 1237

1240

1301

1311

1316

1319

1325

1337

1343

1401

1403

1409

1418 1419

1437

1500 1501

1504

1509

1515

1537

1545

1609

1645

1701

1709

1719

1721

1723

1727

1737

1801

1809

1811

1813

1815

1818 1819

1822 1823

1837

1845

1908 1909

1910

1912

1916 1917

1923

1945

200 2001

2005

2009

201

2019

202

2025

2037

204

2047

208 209

210

2100 2101

2104

2111

2118

212

2137

214

2146 2147

2153

2159

216

2163

218 219

220

2201

221

222 223

2247

2251

2253

2255

2257

2258

226

2261

2262

227

2301

2305

2307

2319

2325

2337

2345

2346 2347

2350

2354 2355

2357

2361

2400 2401

2406

2418

2423

2437

2444 2445

2451

2453

2454 2455

2457

2458

2461

2545

2550

2554 2555

2561

2601

2619

2627

2637

2645

2655

2660

2719

2725

2737

2751

2761

2819

2861

2901

2909

2919

2925

2937

2943

2955

2959

2963

3001301

3015

3021

303

3037

3054 3055

3058

3060 3061

3062

307

313

3154 3155

3157

3159

3160 3161

3163

318 3219

3227

3237

3247

3254 3255

3256 3257

3260 3261

327

3301

3309

3315

3321

3337 3345

3346

3351

3354

3356 3357

3361

3401

3411

3421

3450 3451

3454

3457

3459

3555

3556 3557

3558

3560 3561

3563

3600

3621

3625

3637

3645

3654

3658

3661

3662

3720 3721

3761

3801

3811

3819

3820

3825

3837

3845

3855

3910 3911

3913

3917

3919

3945

3947

3951

3953

3955

3957

3961

400 4001

4005

4009

401

4010 4011

4012 4013

4014

4016 4017

4018

4023

403

4037

4044

4046

405

4050

4052 4053

4054 4055

406

4061

407

408 409

4100 4101

4103

4104 4105

4107

4108

4110 4111

4119

4125

415

4152

4155

4156 4157

4159

4161

4163

4200 4201

4202

4206

4208

4210 4211

4221

4223

4225

4227

4229

425

426

428

4301

4309

4313

4315

4317

4319

4320 4321

4322

4324

4326 4327

4328

4337

4341

4343

4347

4405

4407

4408

4411

4412

4414

4416

4418 4419

4420

4422 4423

4429

4436 4437

4438

4440 4441

4442 4443

4444

4446 4447

4448

500 501

502

502650285030

506 507

508

512651285130

519

522652285230

532653285330

542654285430

552655285530

562656285630

572657285730

582658285830

592659285930

601

602660286030

609

615

619

625

708 709

710 711

712 713

715

719

736 737

739

740 741

742

744 745

746

801

807

808

814

819

825

829

836 837

840 841

901

903

905

911

919

924 925

928

936 937

938

940

943

Hall C Entrance


AAD Food Court

002


INDUSTRY EXPERTS THEATERThese unique sessions provide exhibiting companies the opportunity to present new research findings on products; conduct demonstrations, detail products, and highlight new products. These sessions are solely promotional and are not eligible for continuing medical education credit.

Brought to you by


Brought to you by

©2019 AbbVie Inc. North Chicago, IL 60064 US-RISN-180097 March 2019 Printed in U.S.A.©2019 AbbVie Inc. North Chicago, IL 60064 US-RISN-180097 March 2019 Printed in U.S.A.

EXPERIENCE THE SKY AT BOOTH #2111

001

1000 1001

1002 1003

1004 1005

1009

1019

1021

1037

1041

1043

1045

1047

1100 1101

1103

1105

1109

1118 1119

1123

1127

1129

1136 1137

1138

1140 1141

1142

1144

1200 1201

1204

1209

1217

1218

1222 1223

1224

1236 1237

1240

1301

1311

1316

1319

1325

1337

1343

1401

1403

1409

1418 1419

1437

1500 1501

1504

1509

1515

1537

1545

1609

1645

1701

1709

1719

1721

1723

1727

1737

1801

1809

1811

1813

1815

1818 1819

1822 1823

1837

1845

1908 1909

1910

1912

1916 1917

1923

1945

200 2001

2005

2009

201

2019

202

2025

2037

204

2047

208 209

210

2100 2101

2104

2111

2118

212

2137

214

2146 2147

2153

2159

216

2163

218 219

220

2201

221

222 223

2247

2251

2253

2255

2257

2258

226

2261

2262

227

2301

2305

2307

2319

2325

2337

2345

2346 2347

2350

2354 2355

2357

2361

2400 2401

2406

2418

2423

2437

2444 2445

2451

2453

2454 2455

2457

2458

2461

2545

2550

2554 2555

2561

2601

2619

2627

2637

2645

2655

2660

2719

2725

2737

2751

2761

2819

2861

2901

2909

2919

2925

2937

2943

2955

2959

2963

3001301

3015

3021

303

3037

3054 3055

3058

3060 3061

3062

307

313

3154 3155

3157

3159

3160 3161

3163

318 3219

3227

3237

3247

3254 3255

3256 3257

3260 3261

327

3301

3309

3315

3321

3337 3345

3346

3351

3354

3356 3357

3361

3401

3411

3421

3450 3451

3454

3457

3459

3555

3556 3557

3558

3560 3561

3563

3600

3621

3625

3637

3645

3654

3658

3661

3662

3720 3721

3761

3801

3811

3819

3820

3825

3837

3845

3855

3910 3911

3913

3917

3919

3945

3947

3951

3953

3955

3957

3961

400 4001

4005

4009

401

4010 4011

4012 4013

4014

4016 4017

4018

4023

403

4037

4044

4046

405

4050

4052 4053

4054 4055

406

4061

407

408 409

4100 4101

4103

4104 4105

4107

4108

4110 4111

4119

4125

415

4152

4155

4156 4157

4159

4161

4163

4200 4201

4202

4206

4208

4210 4211

4221

4223

4225

4227

4229

425

426

428

4301

4309

4313

4315

4317

4319

4320 4321

4322

4324

4326 4327

4328

4337

4341

4343

4347

4405

4407

4408

4411

4412

4414

4416

4418 4419

4420

4422 4423

4429

4436 4437

4438

4440 4441

4442 4443

4444

4446 4447

4448

500 501

502

502650285030

506 507

508

512651285130

519

522652285230

532653285330

542654285430

552655285530

562656285630

572657285730

582658285830

592659285930

601

602660286030

609

615

619

625

708 709

710 711

712 713

715

719

736 737

739

740 741

742

744 745

746

801

807

808

814

819

825

829

836 837

840 841

901

903

905

911

919

924 925

928

936 937

938

940

943

Hall C Entrance


AAD Food Court

002


Hall D

▼TO AAD CONNECTION(Poster Exhibits, Resource Center, Networking Lounge)

DermTec, Inc. ............................................. 2861

Dermwise ................................................... 1142

Designs for Vision, Inc. ................................. 500

Dino-Lite Scopes (BigC) .............................. 3255

Doctor Multimedia ....................................... 200

Doctor.com ................................................. 4405

Dow Development Laboratories ................... 3558

DRE Medical Inc ......................................... 3917

Dubai Business Events .................................. 744

E

eClinicalWorks.............................................. 801

Eclipse .......................................................... 925

Eclipse Loupes and Products ......................... 405

eclipserx ..................................................... 4326

Elite Research Network, LLC ......................... 202

Ellis Instruments ........................................ 2301

ELON Hair, Nails & Skin ............................. 1819

Elsevier ....................................................... 3309

EltaMD SkinCare ........................................ 1325

eMIRAmed USA......................................... 2458

EndyMed Medical Inc ................................. 1209

Envy Medical .............................................. 2943

Epionce ...................................................... 1343

Epiphany Dermatology ................................ 1001

Epocrates, an athenahealth service ............... 4163

eRelevance Corp ......................................... 2357

Espada Dermatology subsidiary of Mission Pharmacal ................................. 1845

EunSung Global Corp ................................... 919

European Academy of Dermatology and Venereology ....................................... 100

Evolus, Inc. ................................................. 2147

Excimer Therapies Inc. ............................... 4319

ExoCoBio Inc. ............................................. 4152

EZDerm, LLC ............................................. 3845

F

FDA Center for Drug Evaluation and Research ............................................ 711

Ferndale Healthcare, Inc. ............................ 3301

FibroTx LLC ................................................ 4108

FineMec Co, Ltd ............................................ 409

Foamix Pharmaceuticals ............................. 4301

Focus Medical ............................................. 1218

Forefront Dermatology .................................. 719

FORMATK Systems Ltd .............................. 2159

Fotofinder Systems, Inc ............................... 2719

Fotona Lasers .............................................. 2545

G

Galderma Laboratories, LP ...... 2601, 5026, 5028

Genentech, a Member of the Roche Group ..................................................... 2725

GliSODin Skin Nutrients ............................ 3357

GluStitch Inc. ............................................... 407

Gold Bond Ultimate ...................................... 519

Grand Aespio Inc. ....................................... 4053

GreenSky Patient Solutions, LLC ................. 4436

Guangzhou Huafei Tongda Technology Co., Ltd ..................................................... 713

H

Haircheck ................................................... 3951

HairMax-Lexington International................. 1815

Hansderma ................................................. 4210

Hayden Medical Instruments ........................ 901

Heine USA Ltd ........................................... 3720

Henkel Consumer Goods ............................ 2637

Henry Schein .............................................. 1103

Hidrex USA ................................................ 4014

Hill Laboratories Co. ................................... 3055

Hill Top Research ....................................... 2451

Hironic Co., LTD .......................................... 507

Huons Global ............................................... 745

HydroPeptide ............................................. 2555

I

Iagnosis Inc./DermatologistOnCall ............. 2457

Ibero Latin American Collage of Dermatology/CILAD ................................. 401

ILOODA Co., Ltd .......................................... 400

To Hall D (shown at right)

Please go to aad.org/meetings or the

AAD Meeting Mobile App for the most

up-to-date exhibitor list.


11106200_AAD_Daily_News_Full_Pg_M2.indd 1 1/25/19 12:50 PM

Image Skincare ......................................... 2655

INDIBA, S.A. .............................................. 204

Infinity Massage Chairs ............................... 924

Inform Diagnostics ................................... 2819

Inga Ellzey Billing Companies ................... 3957

Innovaderm Research ................................ 2454

Innovative Optics Laser Eye Protection ....... 2104

Integrated Dermatology Group .................. 3015

International Society of Dermatology ......... 4013

Invitrx Therapeutics .................................. 4438

ISDIN ............................................. 1545, 1645

J

JAMA Network, The .................................. 2305

Jan Marini Skin Research .......................... 3819

Janssen Biotech, Inc. ....................... 3801, 5126

Johnson & Johnson Consumer Inc .....................................3401, 5826, 5828

Journal of Clinical and Aesthetic Dermatology ......................................... 4101

Journey Medical Corporation ..................... 4016

K

Kaiser Permanente .................................... 1916

Kamedis ................................................... 4223

Kao USA Inc. (Bio-Oil) .............................. 2660

Kao-Curel ................................................. 2037

Karger Publishers ...................................... 1401

KCD Medical ............................................. 4328

Kernel Medical ............................................ 905

Kyowa Kirin .............................................. 1043

L

L’Oreal ...................................................... 3345

la parfait cosmetics .................................... 4429

Laboratorio Genove ................................... 3561

Laseroptek Co., LTD. ................................. 2461

Laservision ................................................ 4100

LC Cell...................................................... 2354

LearnSkin ................................................... 739

LEO Pharma Inc. 3227, 3825, 5130, 5226, 5230

LIFTLAB Skin Regeneration ...................... 1041

Light Age, Inc. .......................................... 1419

LightStim .................................................... 318

Lilly USA, LLC .......................................... 2751

Lipotec USA, Inc ....................................... 3955

Locks of Love, Inc. ..................................... 2453

Luma Therapeutics, Inc ............................. 2347

Lumenis ................................................... 1837

LUTRONIC ............................................... 1301

M

M.A. Dermaceuticals ................................. 4322

MartiDerm ................................................ 2261

Mastocytosis Society, Inc., The ................... 1141

Mayne Pharma .......................................... 3855

McGraw-Hill Education ............................. 1822

MCV Physicians-VCU Health ....................... 903

MD Charts, Inc. .......................................... 222

MD Cosmetica .......................................... 4161

Med-Aesthetic Solutions Inc. ...................... 3961

MedCo Data ................................................ 837

Medesthetics Magazine................................ 829

Medicol USA ............................................. 3621

Medjet ...................................................... 3945

Medline Industries, Inc. ............................ 3163

Meridian Clinical Research ........................ 4156

Merz ......................................................... 2937

Mesoestetic SL .......................................... 2258

MetaOptima Technology Inc. ..................... 4320

Microsurgery Instruments, Inc. ................. 3820

Midmark Corporation................................ 2901

Millennium Medical Technologies ............... 218

MiraDry, Inc. .............................................. 911

MJ Products Association LLC ....................... 403

Modernizing Medicine, Inc. ....................... 1237

MolluscumRx. ........................................... 3555

MotherToBaby Pregnancy Studies ................ 220

MTI, Inc. .................................................. 2919

MyDermRecruiter/MyMDRecruiter ........... 4315

Myriad Genetic Laboratories, Inc ............... 1002

N

NAOS/Laboratoire Bioderma ........... 3361, 3459

National Biological Corp. ........................... 2025

National Psoriasis Foundation ..................... 408

Nelly De Vuyst Derme & Co ....................... 4119

NeoStrata Company, Inc. ........................... 3411

Neutrogena ............................................... 3600

New Medical Technology, Inc. .................... 1217

NewBeauty ................................................ 4052

NEWPONG CO., LTD ................................ 4407

Nextech..................................................... 1823

NIA24 ...................................................... 1418

NIAMS ..................................................... 1809

NoIR LaserShield ...................................... 1504

NOURITRESS HAIR PRODUCTS ............. 3161

NovaCutis, Inc. ........................................... 708

Novartis Pharmaceuticals Corporation ....... 3021

Novella Clinical ......................................... 1200

Nutrafol .................................................... 4054

O

Obagi Medical Products ............................. 4125

Oculo-Plastik Inc. ...................................... 1000

OCuSOFT Skin Care ................................... 836

Officite ...................................................... 2345

Omni Bioceutical Innovations .................... 2554

Omnilux ................................................... 4104

Ontos, Inc. ................................................ 1004

Ortho Dermatologics ................................. 3001

Otto Trading Inc ............................. 2146, 3254

Oxygenetix Institute Inc. ............................ 3454

P

Palmer’s .................................................... 4309

PCA Skin .................................................. 3661

Peninsula Medical ....................................... 327

PerfAction Technologies ............................ 3761

Perigee ....................................................... 808

Perimed Inc. ............................................. 4105

Perrigo...................................................... 4050

Person & Covey ......................................... 2406

Pfizer Inc. .........1537, 5426, 5428, 5430, 5526, ................................................... 5528, 5530

Pharma Cosmetics, Inc. ............................. 2325

PharmaDerm a division of Fougera Pharmaceuticals .................................... 2925

Philips Respironics.................................... 3256

PhytoCeuticals, Inc. ................................... 1123

Pierre Fabre USA ...................................... 2423

Pinnacle.................................................... 4341

Practical Dermatology ............................... 2346

Practice Flow Solutions ............................. 4317

PracticeLink ................................................ 840

Precision Medical Devices, LLC.................. 4447

ProCell Therapies ...................................... 4012

Procter & Gamble ..................................... 3037

Proinnovera GmbH ................................... 1118

Promius Pharma ....................................... 3351

ProPath Dermatopathology ........................ 1737

Prostemics Co, LTD .................................. 3947

Providence - Provider Solutions + Development ........................................ 210

PSI/Vanicream Skin Care .......................... 1224

Q

Quanta System SPA................................... 1311

Quantificare .............................................. 2550

Quintessence Skin Science ........................ 1137

R

Ra Medical Systems, Inc. ........................... 2307

Red Spot Interactive .................................. 2163

Refine USA ................................................. 841

Regen Lab ................................................... 619

Regeneron/ Sanofi Genzyme .......3645, 5326, 5328, 5330

Restoration Robotics ................................... 625

Revision Skincare ...................................... 3219

Revitalash ................................................. 2444

Robbins Instruments................................. 1500

Rohrer Aesthetics, LLC ................................ 609

Root of Skin MD by AIVITA Biomedical, Inc. ....................................................... 4420

Rose Micro Solutions....................... 1129, 4229

RoyalZ ...................................................... 2262

S

Saalmann medical GmbH & Co, KG .......... 1021

Sanford Health ............................................ 742

SanovaWorks (including JDD) ................... 4010

Sawgio, LLC .............................................. 4227

Scar Heal .................................................. 1127

Schweiger Dermatology Group .................. 4337

SciBase ..................................................... 4110

SCIENTIST SKINLAB LTD. ......................... 426

Sciton ....................................................... 2100

Sebela Pharmaceuticals Inc. ...................... 3257

Sensus Healthcare ..................................... 4201

Sesderma .......................................... 819, 2619

SESHA Skin Therapy ................................ 3058

Shanghai Wonderful Opto-Electrics Tech. Co., Ltd ........................................ 1140

Shantel Medical Supply ............................. 2418

shenb Co., Ltd ............................................. 506

SILAB ....................................................... 3953

Skagit Regional Health ................................ 214

Skin & Cancer Associates/Advanced Dermatology Mgmt ............................... 1236

Skin Cancer Foundation, The .................... 4001

Skin Disease Education Foundation ........... 1719

SkinCeuticals ............................................ 3337

SkinGen International Inc. ........................ 4107

SkinIO ...................................................... 3662

SkylineDX ................................................... 940

SmartPractice ........................................... 2005

SNJ Co., Ltd ................................................ 219

Society of Dermatology Physician Assistants .............................................. 1912

Solumbra by Sun Precautions .................... 1337

Solvital ...................................................... 3159

Speclipse, Inc. ............................................. 208

Springer ................................................... 3910

STRATA Skin Sciences .............................. 1223

Summit Health ......................................... 4044

Sun Pharma .............................................. 4037

Sun Protection Zone ................................. 2118

SurgiTel/General Scientific Corp. ................. 928

Sutter Health .............................................. 740

Symbio LLC .............................................. 3556

Synergy MedSales ....................................... 221

Synteract ................................................... 2909

Syris Scientific .......................................... 1101

T

taberna pro medicum ................................ 3247

Teoxane Laboratories ................................. 2761

Tergus Pharma, LLC .................................. 4208

The HydraFacial Company......................... 4017

Thermi ....................................................... 501

Tiemann-Bernsco ...................................... 3321

Tizo by Fallene, Ltd ................................... 1437

TKL Research ............................................ 1403

Tooti Enterprise Inc. .................................. 3157

Topix Pharmaceuticals, Inc. ....................... 1515

Toskani SL. ............................................... 4061

Total Clinical Trial Management ................ 3061

Tulip Medical Products .............................. 3563

U

U.S. Dermatology Partners ........................ 3557

UCB, Inc. .................................................... 807

Ultra V CO., Ltd .......................................... 216

Under Skin ............................................... 1945

Unilever ................................................... 2437

UV Skinz, Inc. .......................................... 3154

UVBIOTEK ............................................... 1316

V

Vector Surgical .......................................... 1019

Venus Concept USA Inc. ........................... 1201

VERRICA ................................................. 4046

VI Aesthetics ..................................... 737, 5228

Viscot Medical LLC .................................... 1105

VisualDx ................................................... 3721

Vivacare .................................................... 4159

Viviscal Professional .................................. 4321

Vydence Medical ......................................... 712

W

Wallaroo Hat Company ............................. 1037

Water’s Edge Dermatology ......................... 4324

WCD 2019 Milan ........................................ 226

Wells Fargo Practice Finance ..................... 1144

West-TeleVox Solutions .............................. 1727

Wiley ........................................................ 4408

Wolters Kluwer ......................................... 3811

WON TECH Co, Ltd .................................... 227

X

Xstrahl, Inc. .............................................. 2561

Y

Young Pharmaceuticals, Inc. ...................... 4023

Z

Zero Gravity ...................................... 709, 4200

Zhuhai Yasha Bio Technology Company ..... 1045

Zimmer Medizin Systems ......................... 1409

ZO Skin Health, Inc. ................................. 2201

Data current as of Jan. 10, 2019. Please go to aad.org/meetings or the AAD Meeting Mobile App for the most up-to-date exhibitor list.

11106200_AAD_Daily_News_Full_Pg_M2.indd 1 1/25/19 12:50 PM

© 2019 Allergan. All rights reserved. All trademarks are the property of their respective owners.Allergan.com SkinMedica.com 190396 AGE120684 01/19

These SkinMedica® products are intended to meet the FDA’s defi nition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA, and the statements have not been evaluated by the FDA.

BLUE LIGHT EXPOSUREIS HERE TO STAYBUT WITH THE LUMIVIVE™ SYSTEM, SKIN DAMAGE DOESN’T HAVE TO

LUMIVIVE™ System helps your patients

GET THAT GLOWand keeps them coming back for more.

Defend their skin againstblue light damage all day

Support their skinrecovery at nightblue light damage all dayblue light damage all day recovery at night

Visit SkinMedica® at booth 2401 to learn more.

Sponsored by Celgene

Paul Yamauchi, MD, PhDDermatology Institute & Skin Care CenterSanta Monica, CA

Moving Beyond Topicals: Perspectives on Systemic Treatment for Psoriasis

I N D U S T R Y E X P E R T S E S S I O N

Friday, March 1, 2019 / 12:15 PM - 1:00 PM / 12:15 PM - 1:00 PM Walter E. Washington Convention Center / Washington, DC

This Industry Expert Session is a promotional activity and is not approved for continuing education credit. The content of this session and opinions expressed by presenters are those of the Presenting Company or presenters and do not represent an endorsement by, nor imply that the products have been evaluatedor approved by the American Academy of Dermatology.

Pursuant to the PhRMA Code on Interactions with Healthcare Professionals, attendance at this promotional program is restricted to healthcare professionals. Accordingly, spouses and other guests who are not healthcare professionals may not attend this event. Celgene will report transfers of value made to US healthcare professionals to the extent required by federal and state laws, as applicable. To learn about how Celgene Corporation complies with the Physician Payments Sunshine Act visit http://www.celgene.com/about/compliance/sunshine-act/.

© Celgene Corporation 11/18 US-CLG-18-0496

You’re invited to join the discussion!

PROGRAM FACULTY

© 2019 Allergan. All rights reserved. All trademarks are the property of their respective owners.Allergan.com SkinMedica.com 190396 AGE120684 01/19

These SkinMedica® products are intended to meet the FDA’s defi nition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA, and the statements have not been evaluated by the FDA.

BLUE LIGHT EXPOSUREIS HERE TO STAYBUT WITH THE LUMIVIVE™ SYSTEM, SKIN DAMAGE DOESN’T HAVE TO

LUMIVIVE™ System helps your patients

GET THAT GLOWand keeps them coming back for more.

Defend their skin againstblue light damage all day

Support their skinrecovery at nightblue light damage all dayblue light damage all day recovery at night

Visit SkinMedica® at booth 2401 to learn more.

Sponsored by Celgene

Paul Yamauchi, MD, PhDDermatology Institute & Skin Care CenterSanta Monica, CA

Moving Beyond Topicals: Perspectives on Systemic Treatment for Psoriasis

I N D U S T R Y E X P E R T S E S S I O N

Friday, March 1, 2019 / 12:15 PM - 1:00 PM / 12:15 PM - 1:00 PM Walter E. Washington Convention Center / Washington, DC

This Industry Expert Session is a promotional activity and is not approved for continuing education credit. The content of this session and opinions expressed by presenters are those of the Presenting Company or presenters and do not represent an endorsement by, nor imply that the products have been evaluatedor approved by the American Academy of Dermatology.

Pursuant to the PhRMA Code on Interactions with Healthcare Professionals, attendance at this promotional program is restricted to healthcare professionals. Accordingly, spouses and other guests who are not healthcare professionals may not attend this event. Celgene will report transfers of value made to US healthcare professionals to the extent required by federal and state laws, as applicable. To learn about how Celgene Corporation complies with the Physician Payments Sunshine Act visit http://www.celgene.com/about/compliance/sunshine-act/.

© Celgene Corporation 11/18 US-CLG-18-0496

You’re invited to join the discussion!

PROGRAM FACULTY


Novel Treatment Strategies and the Trial-Based Rationale for

PD-1 TARGETING THERAPY in

ADVANCED and METASTATIC CUTANEOUS SQUAMOUS CELL

CARCINOMA (CSCC)

REGISTER NOW: www.reg-CSCC.com

JOIN US TONIGHT FOR A MILESTONE SATELLITE SYMPOSIUM!World Experts Navigate the Evolving and Complex Landscape of Advanced and Metastatic CSCC

Focus on Real World Cases, High Level Consultation, and Up-to-the-Minute Clinical Trials!

Save the Time and Date: Friday, March 1, 2019Time: 6:30 PM – 9:00 PM | Program Registration and Dinner: 6:30 PM – 7:00 PM

Clinical Program: 7:00 PM – 9:00 PMCity: Washington, DC | Location: Marriott Marquis Washington DC | Address: 901 Massachusetts Avenue NW

Conference Room: Liberty Ballroom M/N/O/P

Supported by an educational grant from Sanofi Genzyme and Regeneron PharmaceuticalsThis program is independent and is not part of the offi cial AAD Annual Meeting, as planned by its Scientifi c Assembly Committee

CMEducation Resources, LLCA Medical Education Company

(CSCC)Focus on the Pathoimmunobiology, Clinical Trials, Translational and Immunotherapeutic

Implications of PD-1 Checkpoint Inhibition in Advanced, Unresectable, and Metastatic Skin Cancers

Program Chairman: TODD E. SCHLESINGER, MD, FAADDirector, Dermatology and Laser Center of Charleston | Clinical Research Center of the Carolinas | Clinical Instructor, University at Bu� alo Department of Dermatology | Assistant Clinical Professor, Medical University of South Carolina Department of Family

Medicine | Clinical Preceptor, Medical University of South Carolina College of Health Professions | Charleston, SC

A YEAR 2019, DERMATOLOGY-FOCUSED, BEST PRACTICE IMMUNO-ONCOLOGY UPDATE FOR THE DERMATOLOGY AND DERMATOLOGIC ONCOLOGY SPECIALIST

T he 2010s have been an inflection point in the diagnosis and treatment

of cutaneous melanoma. FDA-approved checkpoint inhibitors and targeted therapies spurred broad adoption of these new agents across a range of dermatology practices. As the use of these newer systemic agents grew in melanoma and other cancers, dermatologists began to see dermatologic side effects in their own patients, as well as broader populations of cancer patients.

Susan M. Swetter, MD, chaired the interdisciplinary AAD melanoma work group that devoted the last two

years to updating the 2011 AAD guidelines. The current guidelines were published in late 2018 and use the eighth Edition of the American Joint Committee on Cancer melanoma staging system for pathologic diagnosis, as well as

refer to National Comprehensive Cancer Network and other international guidelines for cutaneous melanoma. She will moderate Friday’s “Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines.”

“Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines” (S017)Friday, 1–4 p.m. Room 207B

This is a whole new era for melanoma as we advocate for our patients. A decade ago, we looked at melanoma as a surgically treated disease and hoped to one day find the magic bullet to treat the disease systemically. Now melanoma has become the poster child of cancer for the success of both immunotherapies and targeted therapies.

– Susan M. Swetter, MD

PEARLS FROM MEMBERSPeter Lio, MD Medical Dermatology Associates of Chicago

1234 56AJCC staging changes impact patient selection for sentinel node biopsy in T1 melanoma. The eighth Edition of the staging system is based on a global data set and provides the most accurate long term prognosis available to data. Based on tumor characteristics, patients may or may not be appropriate for adjuvant therapy.

Patients with resected stage III (lymph node) disease, including those detected by sentinel lymph node biopsy, can be treated using anti-PD1 monotherapy with nivolumab, as well as combination BRAF/MEK inhibitors dabrafenib or trametinib. These agents are more effective than previously FDA-approved high-dose interferon or high-dose ipilimumab and far better tolerated.

The new guidelines expand coverage of melanoma and pregnancy. Look for guidance in managing the pregnant woman with melanoma and how a melanoma diagnosis may impact future pregnancies.

The role of genetic testing in melanoma is growing. Single gene and multi-gene testing can help guide treatment in hereditary risk melanoma and for detection and monitoring in cancer syndromes that may include cutaneous melanoma.

Dermatologists should understand the cutaneous toxicity of checkpoint inhibitors and targeted therapies. These agents are now used for melanoma, advanced cutaneous squamous cell carcinoma, and other cancers. The guidelines help clinicians manage these agents more effectively to maintain life-saving and potentially curative therapy.

The latest surveillance data was incorporated into new recommendations for biopsy techniques, pathology evaluation, baseline/surveillance studies, and surgical management, including Mohs micrographic surgery and other staged excision techniques for certain types of melanoma in anatomically challenging locations.

Key updates in new guidelines

Putting patients at ease

C ryotherapy for a wart, administering filler, and

excising an atypical nevus can all bring some pain, discomfort, and anxiety. Using a combination of distraction techniques such as an iPad, topical anesthetics, and excellent local anesthesia (buffered, warmed, and injected slowly along with cooling and vibration to the area) can make an incredible difference. Beyond the patient’s comfort, there is real evidence that the success rate for procedures is actually higher when pain, anxiety, and discomfort are appropriately addressed.”

Learn more at: “Pain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults” (U001)Friday, 7:30–8:30 a.m.Room 146B

key updates in the 2018 melanoma guidelines

Novel Treatment Strategies and the Trial-Based Rationale for

PD-1 TARGETING THERAPY in

ADVANCED and METASTATIC CUTANEOUS SQUAMOUS CELL

CARCINOMA (CSCC)

REGISTER NOW: www.reg-CSCC.com

JOIN US TONIGHT FOR A MILESTONE SATELLITE SYMPOSIUM!World Experts Navigate the Evolving and Complex Landscape of Advanced and Metastatic CSCC

Focus on Real World Cases, High Level Consultation, and Up-to-the-Minute Clinical Trials!

Save the Time and Date: Friday, March 1, 2019Time: 6:30 PM – 9:00 PM | Program Registration and Dinner: 6:30 PM – 7:00 PM

Clinical Program: 7:00 PM – 9:00 PMCity: Washington, DC | Location: Marriott Marquis Washington DC | Address: 901 Massachusetts Avenue NW

Conference Room: Liberty Ballroom M/N/O/P

Supported by an educational grant from Sanofi Genzyme and Regeneron PharmaceuticalsThis program is independent and is not part of the offi cial AAD Annual Meeting, as planned by its Scientifi c Assembly Committee

CMEducation Resources, LLCA Medical Education Company

(CSCC)Focus on the Pathoimmunobiology, Clinical Trials, Translational and Immunotherapeutic

Implications of PD-1 Checkpoint Inhibition in Advanced, Unresectable, and Metastatic Skin Cancers

Program Chairman: TODD E. SCHLESINGER, MD, FAADDirector, Dermatology and Laser Center of Charleston | Clinical Research Center of the Carolinas | Clinical Instructor, University at Bu� alo Department of Dermatology | Assistant Clinical Professor, Medical University of South Carolina Department of Family

Medicine | Clinical Preceptor, Medical University of South Carolina College of Health Professions | Charleston, SC

A YEAR 2019, DERMATOLOGY-FOCUSED, BEST PRACTICE IMMUNO-ONCOLOGY UPDATE FOR THE DERMATOLOGY AND DERMATOLOGIC ONCOLOGY SPECIALIST

BOOTH38012019 AMERICAN ACADEMY OFDERMATOLOGY ANNUAL MEETING

March 1 to 5, 2019

Washington, DC


cp-74266v2_821512_v1b.indd 1 2/11/19 4:56 PM

BOOTH38012019 AMERICAN ACADEMY OFDERMATOLOGY ANNUAL MEETING

March 1 to 5, 2019

Washington, DC


cp-74266v2_821512_v1b.indd 1 2/11/19 4:56 PM


Data on file. ©2019 Beiersdorf Inc.

Triple-action formula enriched with urea30 and ceramides to smooth, soften, and intensively hydrate thick, rough skin

For use on dry, cracked skin, minor wounds and burns, and skin in need

VISIT THE BEIERSDORF BOOTH 2737TO EXPERIENCE OUR BRANDS

C

M

Y

CM

MY

CY

CMY

K

PRO_62308_AAD_Annual_Meeting_Daily_News_Ad_M.pdf 1 1/14/19 11:32 AM

For this session, a laptop with Adobe Flash Player is required. The most effective browsers include Internet Explorer 11 and Firefox on Windows; Mozilla Firefox 29 and Safari 7 on Mac. Please practice using the software in advance by logging onto https://vdpmaterial.nivdp.com/dsb/login.php, using activation key 023.

• Simultaneous access to the clinical information with the ability to toggle between clinical photographs and histological slides.

• Cloud storage allows for global use across congresses, courses, and consultations.

• Can also be used on mobile devices and where available, in EMRs.

• Associated software can also be used to accrue CME credit.

• Software allows for 360-degree rotation of images.• By using crosshairs on the thumbnail image, the area to be

inspected can be located before it is magnified.• In addition to tabs and a slider, double clicking on the image

increases magnification.• Arrows in the upper left corner allow users to toggle between

the histological slide and clinical photographs.

• Software-assisted manipulation of high-definition digital images of tissue sections.

• Simulates the experience of examining glass slides under a microscope and magnification up to x40.

• Viewable by computer, over a network or via the internet.

• Can be used in internet-based exams, such as in the American Board of Dermatology Certification and Re-certification Exams beginning in 2020.

A TED-talks approach to improving practice management and

quality improvement (QI) offers dermatologists a glimpse into the hottest topics facing their practices and their professional reputations within their communities. Amanda Fleming Marsch, MD, assistant professor of dermatology at the University of California San Diego, moderates the session, “Derm Rapid Fire: Putting Residents at the Center of QI Initiative,” covering topics of pressing interest, including patient reviews, DataDerm™, QI in the fee-for-service environment, business administration skills

for optimizing health care, and teledermatology.

A dozen speakers who combine physician skills with MBA credentials will provide the foundation for the financial, analytical, crisis management, and leadership skills professionals will need to excel in their careers and optimize patient care.

At the close of the session, resident recipients of the “AAD Excellence in Patient Care Award” will present their QI projects.

“Derm Rapid Fire: Putting Residents at the Center of QI Initiatives” (S046)Sunday, 1-4 p.m.Salon G

Quality does not equal cost. Quality equals cost savings over time. Going into quality care should be the driver and finances should support that mission, not the other way around.

Amanda Fleming Marsch, MD

“Virtual Dermatopathology Self Assessment: Get Ready For Non-glass Slide Exams” (F022)Friday, 1-3 p.m.Room 143C

Some physicians score higher than others in patient reviews. It may be dependent upon the populations served by the physician. There are some things physicians can control and some they cannot when it comes to scoring.

Demonstrating quality of patient care isn’t always easy. Yet, the game is changing with DataDerm, the Academy’s clinical data registry created by dermatologists, for dermatologists. It’s designed to transform a dermatology practice and elevate the specialty.

Don’t overlook the path to the bottom line. The only way to positively impact

financial results is to focus on delivering quality.

Enhanced leadership skills and improved patient care can be achieved through QI projects, buy-in from all staffing levels, clear communication, budgets, cost analysis, and team management skills.

Teledermatology has its pros and cons. While it’s a cost effective method for connecting physicians and patients, convenient for patients, and reduces wait time, it does increase the risk of HIPAA violations, security breaches, and the potential for misdiagnosis when technology and imaging is poor.

“Rapid-fire” practice management

The wave of change is here. Moving from glass to digital slides for self-assessment and exam settings, as well as electronic medical records and consultations, is happening. Dermatologists who haven’t made the transition will need training. Ellen Mooney, MD, director of the Nordic Institute of Virtual Dermatopathology, will provide the latest on what dermatologists need to know during this afternoon’s session, “Virtual Dermatopathology Self Assessment: Get Ready For Non-glass Slide Exams.” The session includes an introduction to digital pathology and the software that is integral to making the switch, a self-assessment exam that incorporates clinical information, clinical photographs, digital histopathological slides, and an exercise in clinical-pathological correlation. Attendees are given access to real-time training on their laptops.

Sliding into digital

https://vdpmaterial.nivdp.com/dsb/login.php

https://vdpmaterial.nivdp.com/dsb/login.php

Data on file. ©2019 Beiersdorf Inc.

Triple-action formula enriched with urea30 and ceramides to smooth, soften, and intensively hydrate thick, rough skin

For use on dry, cracked skin, minor wounds and burns, and skin in need

VISIT THE BEIERSDORF BOOTH 2737TO EXPERIENCE OUR BRANDS

C

M

Y

CM

MY

CY

CMY

K

PRO_62308_AAD_Annual_Meeting_Daily_News_Ad_M.pdf 1 1/14/19 11:32 AM


So�zone® Syringe TrayCap needles with one hand

Limited show pricing:Booth 1105

www.viscot.com800.221.0658

See demo & save 60%at Booth 1105

E•Z Removable Ink® Skin Marker

Botox® is a registered trademark of Allergan, Inc.

Ink comeso� easily!

1.800.221.0658 • [email protected]

o� easily!Consultations

Botox®

Injectable Fillers

PRO

DU

CT S

POTL

IGH

T

How to beat bureaucracy-induced burnout

T he frustration is real. For many dermatologists, regulatory red tape is

the line in the sand. And an equal number of physicians are unwilling to cross it.

Mark D. Kaufmann, MD, chief medical officer for The Dermatology Group and associate clinical professor of dermatology at Icahn School of Medicine at Mount Sinai, identifies the regulatory, social, and professional forces leading to feelings of frustration, dejection, and hopelessness among dermatologists during Friday’s “Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists.”

Autonomy, authority, and “burdens”“We have two global problems. One is the loss of autonomy and the other is the loss of authority,” Dr. Kaufmann said. “The government is hitting us with regulatory programs, all the acronyms that dermatologists have learned to hate (EHR, HIPAA, etc.). Government has taken the fun out of practicing medicine. That’s a heavy burden on physicians today and explains why some physicians are considering early retirement.”

As part of the audience-focused symposium, experts will join Dr. Kaufmann to discuss a wide range of factors leading to frustration, anxiety, and dissatisfaction for dermatologists, including the impact of government bureaucracy, social media, non-dermatologist encroachment, and false advertising. These “burdens,” as Dr. Kaufmann calls them, take away from patient care.

“The prescription pad has become a suggestion pad. Today, all the regulatory hurdles in front of dermatologists have

stripped away their authority,” Dr. Kaufmann said. “We’re supposed to follow the word of pharmacists and insurance payers. These are people with a fraction of the knowledge we, as physicians, have. Physicians feel frustrated and helpless.”

Creating solutionsIt’s important to formulate strategies for lifelong success and happiness before bureaucracy and burnout take hold, Dr. Kaufmann said. One solution has been to parcel out non-patient care tasks to a third party. That can occur by either selling your practice or maintaining ownership in your practice and outsourcing certain business functions to a management service organization (MSO). Another solution, he says, is to pool your business resources with other practices to share in the day-to-day work of running a practice.

It can be a tough choice for dermatologists, Dr. Kaufmann said. He describes dermatology as the “last hold out for the ‘mom and pop shop’ model.” While some dermatologists may fear selling their practice

to a private equity group or contracting with an MSO, some physicians feel relieved to get back to practicing medicine. And that positively impacts patient care.

“There’s a portion of physicians who are burned out and patients are at risk when physicians feel that way. They may feel as if they are getting the short end of the stick and not getting 110%,” he said. “It’s important to identify if you’re burned out. From my own personal experience, now that I’ve unloaded my burdens of the business portion of my practice life, I feel much less burned out and much better.”

Dr. Kaufmann predicts the “mom and pop” model of dermatology will continue to transform into larger systems.

“Find a system you are comfortable in, minimize your non-clinical duties, and you will become happy again,” he said.

“Bureaucracy, Compliance, and Burnout: What it Means to Dermatologists” (S015)Friday, 1-4 p.m.Room 140A

Career Networking Event The AAD Career Networking EventFriday, from 4:30-6:30 p.m. Marquis Ballroom Salon 6, Marriott Marquis.

Meet with more than 50 employers from around the country who are looking to hire during this high-energy event. You can also get a complimentary CV review, learn about AAD’s Career Center, and explore practice setting opportunities. CeraVe is a registered trademark.

©2019 CeraVe LLC CVE.D.P.0107

REFERENCES: 1. Takikawa M, Inoue S, Horio F, Tsuda T. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. J Nutr. 2010;140(3):527-533. 2. Morgan N. What you need to know about xerosis in patients with diabetic feet. Wound Care Advisor. https://woundcareadvisor.com/what-you-need-to-know-about-xerosis-in-patients-with-diabetic-feet_vol2-no4/. Accessed June 25, 2018.

Developed with dermatologists for individuals with diabetes to help moisturize and soothe dry skin.

Bilberry• Has antioxidant properties1

• Is a source of lactic and ascorbic acid

Urea• Helps facilitate exfoliation2

• Helps moisturize and promote smoother skin

DRY TO VERY DRY SKIN

AND HELP

RESTORERELIEVE

Formulated with ceramides 1, 3, & 6-ll to help repair and restore the natural skin barrier, CeraVe offers over 70 different skincare products.

VISIT BOOTH #3337 TO SEE MORE.

Mark D. Kaufmann, MD

CeraVe LLC IBCpage 27

CeraVe is a registered trademark. ©2019 CeraVe LLC CVE.D.P.0107

REFERENCES: 1. Takikawa M, Inoue S, Horio F, Tsuda T. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. J Nutr. 2010;140(3):527-533. 2. Morgan N. What you need to know about xerosis in patients with diabetic feet. Wound Care Advisor. https://woundcareadvisor.com/what-you-need-to-know-about-xerosis-in-patients-with-diabetic-feet_vol2-no4/. Accessed June 25, 2018.

Developed with dermatologists for individuals with diabetes to help moisturize and soothe dry skin.

Bilberry• Has antioxidant properties1

• Is a source of lactic and ascorbic acid

Urea• Helps facilitate exfoliation2

• Helps moisturize and promote smoother skin

DRY TO VERY DRY SKIN

AND HELP

RESTORERELIEVE

Formulated with ceramides 1, 3, & 6-ll to help repair and restore the natural skin barrier, CeraVe offers over 70 different skincare products.

VISIT BOOTH #3337 TO SEE MORE.

COME FOR THE DATA STAY FOR THE RESULTS

80 mg/mL

80 mg/mL

Learn about the Taltz Savings Card Program at taltz.com/hcp

Taltz® is a registered trademark of Eli Lilly and Company. PP-IX-US-2573 01/2019 ©2019, LILLY USA, LLC. ALL RIGHTS RESERVED. PRINTED IN USA ON POST-CONSUMER RECYCLED PAPER

If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company’s Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.

This program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee.

EVENT NAME: ONGOING EXPERIENCE WITH TALTZ (IXEKIZUMAB) INJECTION EFFICACY AND SAFETY—AAD UPDATE MARCH 2, 2019 | 7:00 PM – 8:30 PM Renaissance Ballroom East | Renaissance Washington, DC Downtown Hotel

Washington D.C. PRESENTED BYCraig L. Leonardi, MDAdjunct Professor of Dermatology, St. Louis University & Jennifer Cather, MD, FAADMedical Director, Mindful Dermatology

Sponsored by Lilly USA, LLC

MEET TALTZ AT BOOTH 2751

PP-IX-US-2571 HCP - P2P Product Theater Journal Ad-2019.indd 1 31/01/19 10:03 PM

AAD in D.C.: Networking Event Career Dermatology at its finest · 6 American Academy of Dermatology. Meeting. “

Documents